Bupropion’s Bioinequivalence: Patient Variability, Absorption, and Metabolism. by Connarn, Jamie Nicole
 Bupropion’s Bioinequivalence: Patient Variability, Absorption, and Metabolism 
 
by 
Jamie Nicole Connarn 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of  
Doctor of Philosophy 
(Pharmaceutical Sciences) 
in the University of Michigan 
2015 
 
 
 
 
 
 
 
Doctoral Committee: 
 Professor Duxin Sun, Chair 
 Professor Gordon L. Amidon 
 Professor Vicki L. Ellingrod 
 Professor David E. Smith 
  
 ©Jamie N. Connarn 
2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
Dedication 
 
To my family for all their love, prayers, and support; especially my Mom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Acknowledgements 
  
First and foremost, I would like to thank my advisor, Dr. Duxin Sun for all the 
remarkable opportunities that he gave me during my graduate career as well as the full 
support and training.  Without all his support, knowledge, and dedication to producing 
successful graduate students, this would not be possible.   
I would like to thank my committee members; Dr. David Smith, Dr. Gordon 
Amidon, and Dr. Vicki Ellingrod for all their insightful expertise in guiding my research 
smoothly.  I would also like to thank Dr. Jason Gestwicki, who was a huge help on my 
Heat Shock Protein studies.  In addition, I would like to thank Dr. Rose Feng, Dr. Simon 
Zhou, and Dr. Yan Li for collaborative projects and all the assistances with my PK 
analysis.  I am grateful for all my lab mates and staff; Hayley Paholak, Joe Burnett, 
Becky Reed, Xiaoqing Ren, Kanokwan Sansanaphongpricha, Albert Lin, Mari 
Gasparyan, Alex Yu, Ila Myers, Nathan Truchan, Huixia Luo, Dr. Hongwei Chen, Dr. 
Ruijuan Luo, Dr. Ting Zhao, Dr. Bo Wen, Dr. Siwei Li, Dr. Xiaoqin Li, Dr. Yasuhiro 
Tsume, Marisa Gies, and Gail Benninghoff.  In addition, I would like to thank those who 
were a part of our large clinical team; Marisa Kelly, Gloria Harrington, Stephanie 
Flowers, Kirsten Weiss, Xinyuan (Susie) Zhang, and Andrew Babiskin    
I would like to express how grateful I am for all of my friends I have met here; 
Xiaomei Chen, Amy Doty, Morgan Giles, Kelly Hansen, Eric Lachacz, Maya Lipert, Max 
Mazzara,  Allison Maytas, Max Stefan, Charlie Steffens, Arjang Talattof, Karthik 
Pisupati, Maria Posada, and too many more.  I will always remember our great times 
 
 
iv 
 
together in Ann Arbor.  A special thanks to two of my best friends who helped me 
through many times over years; Melissa Benham and Maryann Oram.       
Finally, I would like to thank all of my family especially; my parents Leslie Persin 
and Jim Connarn and my sister Jennifer and Jessica Connarn for their love and support.   
 
 
 
 
 
v 
 
TABLE OF CONTENTS 
Dedication ........................................................................................................................ii 
Acknowledgements ......................................................................................................... iii 
List of Figures ..................................................................................................................vi 
List of Appendices ...........................................................................................................ix 
List of Abbreviations ........................................................................................................ x 
Abstract .......................................................................................................................... xii 
 Background and Introduction ......................................................................... 1 Chapter 1
 Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine ... 22 Chapter 2
 Method Development, Validation, and Sample Analysis of Bupropion in Chapter 3
Human Plasma. ............................................................................................................. 60 
 Investigate Different Release Mechanisms that May Alter Absorption, Chapter 4
Metabolism, and Pharmacogenomics of Bupropion. ..................................................... 81 
 Conclusions ............................................................................................... 108 Chapter 5
Appendices   .............................................................................................................. 113  
 
 
 
vi 
 
List of Figures 
Figure 1-1.  Subcellular Fractions.  ............................................................................... 20 
Figure 1-2.  Generics Failed BE Standards.   ................................................................ 21 
Figure 2-1.  Bupropion and Metabolism. ....................................................................... 48 
Figure 2-2.  Method Development for Bupropion and Metabolites.. .............................. 49 
Figure 2-3.  Hydroxybupropion Metabolite Formation in Liver Subcellular Fractions. ... 50 
Figure 2-4.  Threohydrobupropion Metabolite Formation in Liver Subcellular Fractions.
 ...................................................................................................................................... 51 
Figure 2-5.  Erythrohydrobupropion Metabolite Formation in Liver Subcellular Fractions..
 ...................................................................................................................................... 52 
Figure 2-6.  Threohydrobupropion Metabolite Formation in Intestinal Subcellular 
Fractions..  . .................................................................................................................. 53 
Figure 2-7. Threohydrobupropion Metabolite Formation in Intestinal Subcellular 
Fractions.. ..................................................................................................................... 54 
Figure 2-8. Enzyme Expression in Human Subcellular Fractions.   ............................... 55 
Supplemental Figure 2-1.Hepatocytes Kinetics.   .......................................................... 58 
Figure 3-1.  MRM Chromatograms of Blank Plasma Samples for Selectivity.. .............. 71 
Figure 3-2.  MRM Chromatograms of Blank Samples with IS for Selectivity.. ............... 72 
Figure 3-3. Specificity for Bupropion and Metabolites. .................................................. 73 
Figure 3-4. Short term stability.  . .................................................................................. 79 
Figure 3-5.  Carryover.  . ............................................................................................... 80 
Figure 4-1. Time vs Concentration Plots.   .................................................................... 98 
Figure 4-2.  Relative Bioavailability. .............................................................................. 99 
Figure 4-3.  Analysis of Metabolites .. ......................................................................... 100 
Figure 4-4.  Pharmacogenomics of CYP2B6.  . ........................................................... 101 
Figure 4-5.  Weibull Absorption Rate........................................................................... 102 
Figure 4-6. Cumulative Percent Absorbed.. ................................................................ 103 
Appendix Figure 1-1.  HSP90 Complex.                                                                  130 
Appendix Figure 2-1.  SRL-PFAC confirm that both Hsp70-PP5 and Hsp90-PP5 
interact. ....................................................................................................................... 155 
Appendix Figure 2-2.  Fluorescence polarization confirms that Hsp90-PP5 has higher 
affinity than Hsp70-PP5.. ............................................................................................. 156 
Appendix Figure 2-3.  Competition studies confirm binding data.. .............................. 157 
Appendix Figure 2-4.  Hsp70-PP5 and Hsp90 interact with different stoichemetries.. 158 
Appendix Figure 2-5.  C-terminal residues of Hsc70 bind PP5.. ................................. 159 
Appendix Figure 2-6.  Hsp70 preferentially stimulates PP5’s phosphatase activity.. .. 160 
 
 
vii 
 
Appendix Figure 3-1.  Fluorescence Polarization Assay.. ........................................... 177 
Appendix Figure 3-2.  Primary Screen of TPR containing proteins-Hsp90 peptide. .... 178 
Appendix Figure 3-3.  Dose Response Curves from Hit Compounds. ........................ 179 
Appendix Figure 3-4. Hits from DRC.. ......................................................................... 180 
Appendix Figure 3-5. Suramin inhibits TPR containing proteins-Hsp90.  . .................. 181 
Appendix Figure 3-6.  Sumarin and Analogs for inhibiting Hsp90-TPR containing 
proteins.. ..................................................................................................................... 182 
 
 
 
 
viii 
 
List of Tables 
Table 2-1. Summary of Subcellular Kinetics..                                                             56 
Table 2-2.  Estimated Intrinsic Clearance.. .................................................................... 57 
Supplemental Table ‎2-1.  Hepatocytes Kinetics Summary...................................... ...... 59 
Table 3-1.  MRM Parameters.  . .................................................................................... 70 
Table 3-2.  Standard Curves for Bupropion and Metabolites.. ....................................... 74 
Table 3-3.  Matrix Effect Analysis.  . .............................................................................. 75 
Table 3-4.  Accuracy.  . ................................................................................................. 76 
Table 3-5.  Precision.   .................................................................................................. 77 
Table 3-6.  Recovery.  . ................................................................................................. 78 
Table 4-1.  Area Under the Curve.. ............................................................................. 104 
Table 4-2.  Percent of Relative Bioavailability.   .......................................................... 105 
Appendix Table 1-1.  Co-Chaperones that bind to HSP90.. ........................................ 131 
Appendix Table 3-1.  Summary of Primary Screen for TPR-Hsp90.  .......................... 183 
Appendix Table 3-2.  Summary of Dose Response Screen for TPR domain- Hsp90 
peptide.  . .................................................................................................................... 184 
 
 
 
ix 
 
List of Appendices 
 Introduction to HSP70/ HSP90 ................................................................ 113 Appendix 1
 The Molecular Chaperone Hsp70 Activates Protein Phosphatase 5 (PP5) Appendix 2
By Binding the Tetratricopeptide Repeat (TPR) Domain ............................................. 132 
 High Throughput Screening for Small Molecules to Block TPR containing Appendix 3
Co-chaperones- Hsp90 Chaperone Complex ............................................................. 163 
 
 
x 
 
List of Abbreviations 
ANDA: Abbreviated new drug application 
AUC: Area under the curve 
CE: Collision energy 
CLint: Intrinisic clearance 
BE: Bioequivalence 
BUP: Bupropion 
CHIP: C- terminus of HSC70- Interacting Protein 
CI: Confidence intervals 
CR: Carbonyl reductase 
CYP: Cytochrome P450 
CYP2B6: Cytochrome P450 2B6 
DAT: Dopamine transporter 
DP: Declustering potential 
DRC: Dose response curves 
E-BUP: Erythrohydrobupropion 
EP: Entrance potential  
ESI: Electron spray ionization 
FDA: Food and Drug Administration 
GI: Gastrointestinal 
H-BUP: Hydroxybupropion 
HOP: Hsp70- Hsp90 Organizing Protein 
HSP: Heat shock protein 
 
 
xi 
 
IR: Immediate release 
IS: Internal standard 
LC: Liquid chromatography 
LLOQ: Lower limit of quantification 
MDD: Major depressive disorder 
Min: Minutes 
MR: Modified release 
MRM: Multiple reaction monitoring 
MS: Mass spectrometry 
NET: Norepinephrine transporter 
PK: Pharmacokinetics 
PPI: Protein-protein interactions 
T-BUP: Threohydrobupropion 
XL or ER: Extended release 
 
 
xii 
 
Abstract 
Bupropion is a clinically available drug product, marketed as Wellbutrin and 
Zyban.  Bupropion is a norepinephrine/dopamine reuptake inhibitor used for major 
depressive disorder, seasonal affective disorder, and smoking cessation.  A single dose 
bioequivalence (BE) study was performed for generic versions of bupropion and the 
name brand product, Wellbutrin.  Due to dose related seizures associated with the 300 
mg dose, BE studies with the 150 mg dose was extrapolated to the 300 mg dose.  
However, after complaints of lack of efficacy and adverse effects, the FDA conducted a 
pilot study on one generic (Budeprion 300 XL) with Wellbutrin 300 XL where it was 
found that some of the 300 mg generic formulations were bioinequivalent.  Therefore, 
the purpose of these studies was to understand how absorption, metabolism/ metabolic 
enzymes expression, and patient variability influenced bupropion’s pharmacokinetics.  
Bupropion produced three active metabolites via two separate pathways, cytochrome 
P450 2B6 and carbonyl reductase.  We compared the relative contribution of the two 
metabolic pathways of bupropion (by cytochrome P450 2B6 and carbonyl reductase) in 
the subcellular fractions of liver and intestine, investigated the difference of bupropion’s 
metabolism in both liver and intestines, and identified which carbonyl reductases might 
be responsible for bupropion’s metabolism.  Secondly, we looked at healthy individuals 
to see how differences in both enzyme expression (such as polymorphisms in 
cytochrome P450 2B6) and various formulations (immediate, sustained, or extended 
release) can affect the pharmacokinetics of bupropion and metabolites in humans.  
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  Chapter 1
Background and Introduction 
 
1.1 Introduction to Bupropion 
Bupropion HCl is a clinically approved drug that is used for treatment of major 
depressive disorder (MDD), smoking cessation, and seasonal affective disorder.  
Bupropion was first marketed as Wellbutrin in the late 1980’s by GlaxoSmithKline [1].  
Bupropion, a non-tricyclic antidepressant, is a nonselective inhibitor of dopamine (DAT) 
and norepinephrine (NET) transport [2].  It is also thought that bupropion is an 
antagonist of the neuronal nicotinic acetylcholine receptor (nAChR) which contributes to 
its use as a smoking cessation drug [3].  Currently, over 11 million prescriptions of 
bupropion have been issued annually [4, 5].  Bupropion was initially released as an 
immediate release product that was dosed 3 times daily.  In 1996, a sustained release 
formulation (dosed twice daily) and in 2003 an extended release formulation (dosed 
once daily) were approved [6].  One risk that is associated with bupropion is dose 
related seizures, particularly it was thought to start at doses of 300 mg and higher [7].  
In addition to seizures, other side effects have been associated such as headaches, dry 
mouth, and insomnia [8].        
 
 
  
 
 
2 
 
1.2 Pharmacology 
Bupropion is a free base with a molecular weight of 239.74 g/mole (bupropion 
HCl, 276.2 g/mol).  The logP of bupropion HCl at 37 ºC in n-octanol water solution at pH 
7 is 3.4 and the pKa of bupropion is 7.9.  Bupropion is highly soluble in water at 312 
mg/mL.   
There has been some debate on bupropion’s true mechanism [9].  It has been 
proposed that bupropion is a nonselective inhibitor of DAT and NET transporters [2].  
Based on studies using positron emission tomography, bupropion and its metabolites 
have been shown to act on the DAT in the brain.  However, the occupancy was found to 
be low (6-22%) for DAT; this has raised questions whether therapeutic levels can be 
reached for efficacy or whether another mechanism of action is involved [10].  Other 
studies have revealed that bupropion may act as a noncompetitive nicotinic antagonist, 
which would explain the efficacy as smoking cessation agent [11, 12]. However, unlike 
many antidepressants that are typically selective serotonin reuptake inhibitors, 
bupropion has been associated with less severe side effects including; sexual 
dysfunction, suicidal depression,  fatigue, and sleepiness [13-15]; which makes it a 
popular choice.   
Due to the metabolism of bupropion, it has been found that bupropion has 
potential drug interactions with ritonavair, efavirenz, and nelfinavir [16].  It has also been 
shown that bupropion is a strong CYP2D6 inhibitor and therefore should be avoided 
when taking other drugs that may be metabolized by CYP2D6 [17].  Therefore, one 
should be cautious about dosing bupropion with multiple medications as it might have a 
drug-drug interaction or drug-enzyme interaction.   
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1.3 Pharmacokinetics of Bupropion 
Bupropion is rapidly absorbed after oral administration [18].  For the immediate 
release formulation, the mean Tmax for bupropion is ~1.5 hours.  For the sustained 
release and the extended release, the absorption is prolonged to having an estimated 
Tmax of about ~3 and ~5 hours respectively [19].  The mean elimination half-life of 
bupropion is 21 ± 9 hours [20]. Bupropion is vastly distributed throughout the body; the 
volume of distribution at steady state is 19 L/kg and it has an estimated total clearance 
of 36 mL/min/kg.  The protein binding of bupropion to human plasma is about 82-88% 
[19].   
Bupropion goes through extensive first pass metabolism to form 3 primary active 
metabolites; hydroxybupropion, threohydrobupropion, and erythrohydrobupropion.  The 
metabolites exhibit less protein binding compared to the parent drug bupropion; 
hydroxybupropion 77% and threohydrobupropion 42% [21].   Hydroxybupropion has an 
elimination half-life is on the same order as bupropion (~20 hours) [20].  However, both 
threohydrobupropion and erythrohydrobupropion have a longer half-life of ~33 and ~35 
hours respectively [20].  For more details on the metabolism, see the metabolism 
section below.  
For multiple doses of bupropion, it takes about 7-10 days to reach steady state.  
Bupropion is mainly excreted in urine via metabolites.  In fact, 87% of bupropion is 
eliminated in urine but only 0.5% is unchanged [19].  Similarly, 10% of bupropion is 
eliminated in feces but <0.1% is unchanged [18].   One study looked at elimination of 
bupropion in urine after a single dose, they found that of the total recovery, bupropion 
consisted of 0.6% and hydroxybupropion consisted of 2.8%; in total these two analytes 
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constituted 3.6% of total drug recovered (threohydrobupropion or 
erythrohydrobupropion were not quantified in this study) [22].  This suggests that the 
three major metabolites may further be metabolized before elimination, but studies have 
yet to confirm this. Studies on hepatic or renal impairment have been investigated, yet 
the clinical implications of these have not been fully translated. For renal impairment, 
one study suggested patients should be administered a lower dose of bupropion.  
Reasons for this have yet to be completely understood however, one hypothesis was 
due to CYP2B6 metabolism activity, yet this would further need to be explored [23].  In 
rats, they found that hepatic impairment lead to bupropion exhibiting a Cmax 3 times 
higher than control, an AUC increase of 4-5 times compare to control, and the half-life 
twice a long [24].  Again, translating this to humans would need to be investigated.  
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1.4 Metabolites 
Bupropion forms three primary active metabolites by CYP450 2B6 (CYP2B6) and 
carbonyl reductase (CR).  Hydroxybupropion is formed by CYP2B6 metabolism via 
hydroxylation of the tert-butyl group and threo/ erythrohydrobupropion are formed when 
bupropion is metabolized by CR.  Using an in vitro microsome assay, the major 
metabolite has been reported to be hydroxybupropion [22, 25].   Additional kinetics 
studies evaluating metabolite formation (hydroxybupropion, threohydrobupropion, and 
erythrohydrobupropion) in liver fractions have been performed [26, 27]. 
The metabolism of this drug has been very important to consider in terms of 
clinical efficacy since all 3 of these metabolites are thought to be active and have shown 
to have as much 25-50% activity of the parent drug using an animal model [28, 29].  In 
addition, hydroxybupropion and threohydrobupropion have shown to have higher 
plasma concentrations compared to bupropion after a single oral dose (and therefore, 
higher AUC) [20].    
The diastereomers, threohydrobupropion and erythrohydrobupropion have not 
been fully characterized in terms of formation (in vitro), activity, or potency.  However, 
for both in vitro studies and in vivo plasma samples, threohydrobupropion formation/ 
concentration were shown to be higher than erythrohydrobupropion; in fact 
erythrohydrobupropion concentration in plasma is very low.  Likewise, stereochemistry 
may play an important role for hydroxybupropion.  Hydroxybupropion can exist as (2S, 
3S) or (2R, 3R) (typically (2S, 3R) or (2R, 3S) does not exist due to steric hindrance).  
One group looked at the clearance of the enantiomer of hydroxybupropion in urine and 
plasma; in plasma, 95% of total hydroxybupropion existed as the R,R form and of the 
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total hydroxybupropion in urine, 72% existed in the R,R form [30].  In a different study, 
they evaluated the formation of enantiomers of hydroxybupropion in vitro.  Using human 
liver microsome and recombinant CYP450’s, studies revealed a 3 fold higher formation 
rate of the S,S hydroxybupropion compared to R,R hydroxybupropion [22].  Although 
these studies conflict, it is important to recognize and to keep in mind because of the 
impact it might play clinically.   
    
1.4.1 Metabolic Enzymes Review 
Cytochrome P450 2B6 
CYP2B6 has emerged as an important metabolic enzyme in the liver in the past 
several years.  In fact, it is now thought that CYP2B6 might account for 2-10% of total 
hepatic metabolism [31].  Similar to most CYP enzymes, CYP2B6 is primarily expressed 
in the liver and contributes to first pass metabolism.  It has also been suggested that 
CYP2B6 might be expressed in brain, kidney, intestine, endometrium, skin, and others 
[32-34].  However, the degree at which they are expressed (if at all) and whether they 
exhibit any activity to contribute to the metabolism of CYP2B6 substrates is unknown.   
Like previously mentioned, this enzyme is an important for metabolizing bupropion to 
form hydroxybupropion.   
CYP2B6 is highly polymorphic, showing over 20-250 fold variability in expression 
and activity [31].  Moreover, several in vitro studies looked at the various formation of 
hydroxybupropion using liver microsome; they saw a 45-80 fold change in metabolite 
formation and a 100 fold difference in the corresponding protein expression of CYP2B6 
[35, 36].  Many studies also indicated that drug-drug interactions might affect CYP2B6 
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metabolism and thus hinder formation of hydroxybupropion [25].  Therefore, this 
inhibition could potentially cause too much toxicity from additional exposure of the 
bupropion.  CYP2B6 variants have started to be investigated over the past decade; 
however, the functions of these variants on metabolism have still not been fully 
characterized.  It has been proposed that CYB2B6 *4 and *22 might be high metabolizer 
whereas CYP2B6 *5 and *6 might be poor metabolizers [37].  The literature has tried to 
unravel what might cause inter-patient variability in CYP2B6.  For instances, it has been 
shown that ethnicity and gender can impact the variants an individual expresses.  In 
Asians, CYP2B6 has been shown to have higher frequency compared to the African 
American population [38].  Additionally, sex differences have been observed where 
females have a high protein expression (1.7 fold) and activity (1.6 fold) of CYP2B6 *4 
compared to males [39].  In fact, one study looked at the pharmacokinetics of bupropion 
in 75 adolescents after a single dose of a sustained release formation and found that 
adolescent females had higher formation of hydroxybupropion compared to adolescent 
males [40].   
 In conclusion, many factors can contribute to the genetic and environmental 
factors that influence the CYP2B6 metabolism of bupropion.  Moreover, there have 
been studies that suggest that other CYP isoforms might have roles in the metabolism 
of bupropion (particularly forming hydroxybupropion) including CYP2E1, and CYP3A4 
[41].  However, it’s unclear to date if these have any impact in vivo.    
    
Carbonyl Reductase 
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  CR also play a big role in the metabolism of bupropion.  To date, it’s not clear 
which carbonyl reductase enzyme(s) is (are) involved in this metabolism.  CR enzymes 
have been divided into two families that encode for CR genes; aldo-keto reductases 
(AKR) and the short-chain dehydrogenases/reductases (SDR) where there are about 6-
7 different enzymes in each family [42, 43].  Combined, these two families have a total 
of 12 enzymes involved in the reductive metabolism of carbonyl compounds [42].  
These reactions are typically carried out in an NAD(P)(H)- dependent state and majority 
of these enzymes are localized in the cytoplasm [42].  To date, very little is known about 
this enzymatic pathway and its role in bupropion’s metabolism.  Recently one study 
looked at the role these enzymes have on bupropion in vitro using liver microsomes and 
cytosolic fractions.  The study proposed that CR can catalyze microsome liver fraction 
to form erythrohydrobupropion at Km=149 ± 24 µM (Vmax=30.2 ± 1.2 pmol/mg of 
protein/min) and threohydrobupropion at Km 62 ± 7µM (Vmax=756.2 ± 17.9 pmol/mg of 
protein/min).  However, their kinetic data contradicts much of literature, by showing that 
threohydrobupropion forms at nearly 7 fold higher than hydroxybupropion.  They also 
suggest that the following CR enzymes;  11 β-hydroxysteroid dehydrogenase1, 
AKR1C1, AKR1CS, AKR1C3, and CBR1 might participate in the reduction of bupropion 
in vitro using recombinant forms of cytosolic CR enzymes [27], however, this needs to 
further be confirmed.     
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1.5. In vitro systems for studying drug metabolism  
There are various organs in the body such as liver, kidney, lungs, or intestines 
responsible for drug metabolism.  The biotransformation of compounds typically occur 
as 1) phase 1 metabolism (including oxidation, reduction, and hydroxylation) or 2) 
phase 2 reaction (including conjugation).  The purpose of these reactions are to make 
compounds more hydrophilic (water soluble) so that they can be eliminated [44].  
Although, drug metabolism can occur in various tissues, the liver is the primary organ 
for metabolism [45]. In vitro drug metabolism has been highly important in preclinical 
drug development due to the high throughput (compared to in vivo) and the vast 
information that can be studied in vitro (metabolism identification, metabolite kinetics, 
etc) [46].  Once centrifugation technique were available, it was possible to separate 
organelles to measure metabolism; particularly one popular technique has become 
microsomes stability assays.  Microsomes are vesicles that reform from pieces of the 
endoplasmic reticulum that contain many phase 1 metabolism enzymes (making 
xenobiotics more polar), including Cytochrome P450’s (CYP450).  Microsome stability 
assays have been a cheap, reproducible, and easy way to evaluate xenobiotic 
metabolism [47, 48]. However, phase II metabolism typically occurs at a lesser extent 
compared to CYP metabolism and these enzymes are not always localized in 
microsomes but rather cytosolic, mitochondria, or other organelles.  For measuring this 
metabolism, cytosolic fraction or S9 fraction might be useful.  S9 fraction, which is a 
post mitochondrial supernatant fraction, contains both microsomes and cytosolic 
fraction (Figure 1).  This fraction contains both phase I and phase II metabolites.  
Typically reactions seen in microsomes will also occur in S9 fraction but at a lesser 
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degree; this is because it is thought that CYP activity in S9 fraction is 20-25% of that in 
microsomes [49]. In addition to these subcellular in vitro assays, hepatocytes (cellular 
organelle) are a common way to measure metabolism.  It has been observed that there 
is a good correlation between metabolism between in vitro hepatocyte studies and in 
vivo, likely due to the fact that the cells are intact [50].  Hepatocytes are more ideal 
system because they contain all metabolism enzymes and transporters.  However, they 
also present more challenges such as low through put, harder to culture, and are 
typically expensive.   
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1.7. Bioequivalence  
 In order for generic drugs to become approved, manufactures must file an 
abbreviated new drug application (ANDA).  For generics to be approved, bioequivalence 
studies (BE) are performed to ensure that the generic and name brand drug are 
equivalent.  The Food and Drug Administration (FDA) defines bioequivalences as “the 
absence of a significant difference in the rate and extent to which the active ingredient 
or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes 
available at the site of drug action when administered at the same molar dose under 
similar conditions in an appropriately designed study” [52].  A typical study for BE to be 
approved by FDA includes a test (generic drug) to reference (name brand drug) single 
dose cross-over study design [53].  In order to be approve to sell to market, the test 
product must stay within a 90% confidence interval of 80-125% for both the area under 
the curve (AUC) and Cmax.  The FDA Guidance for Industry: Bioavailability and 
Bioequivalence Studies for Orally Administered Drug Products highlights some 
biowaiver criteria to be exempt from testing at the highest strength for ANDA.  These 
include linear elimination kinetics over a therapeutic dose range, test and reference 
shows similar dissolution, and the higher strength of the test and reference products are 
proportionally similar to the lower strengths.  For BE testing, there has been concern 
whether this criteria is strict enough to ensure similar therapeutic equivalences, 
particularly relating to narrow therapeutic index drugs and capturing the rate of 
absorption  [54-58].  In fact, it is thought that with modified release products, current BE 
standards fail to reproduce therapeutic equivalence.  One study highlighted this using 
two drug products, methylphenidate and nifedipine.  They showed by using an extra 
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metric, partial AUC, differences were seen using a plasma concentration vs time profile 
where no differences were observed using current standards [59].  The partial AUC is 
calculated by looking at the plasma concentration vs time profile from time 0 to the 
median time to reach Tmax and applying the same 90% CI interval of 80-125% between 
test and reference product [60].  To date, partial AUC is not a requirement for approval 
of generic drugs (for either IR or MR) but highly recommended.  In some circumstances 
such as vast differences in the shape of the concentration vs time profile, the FDA may 
recommend partial AUC.          
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1.8. Regulation issues 
When Wellbutrin came off patent, many generics were approved by the FDA 
including the following manufactures; ANCHEN Pharms, EDGEMONT Pharms, IMPAX 
Labs, Mylan, Sandoz, Sun Pharma Global, Valeant Intl, Watson Labs, Wockhard Ltd, 
and Apotex Inc at doses ranging from 75-300 mg in either, IR, SR, or ER [61].  These 
generics were approved using BE standards comparing bupropion generics to 
Wellbutrin.  In order for these generic products to be BE, the 90% confidence interval of 
the pharmacokinetic parameters Cmax and AUC of the generic to name brand means 
need to be within 80-125%.   
Since there was concern that bupropion at a 300 mg dose had a greater risk for 
seizures, BE studies for the ER generics were conducted at the 150 mg ER in healthy 
volunteers.  The data was extrapolated from the 150 mg dose to the 300 mg dose 
based on the criteria for biowaivers.  The 150 mg dose were BE and approved to sell 
and based on the extrapolated data the 300 mg ER generics were also passed BE and 
were approved to sell to market.     
Shortly after, many generics of bupropion came to market including one, 
Budeprion 300 mg XL (Impax Labs distributed by Teva).  After some patients switched 
to a few of these generics, the FDA received many complaints in regards to adverse 
events, loss of antidepressant effects, headaches, gastrointestinal disorder, fatigue, and 
anxiety particularly with Budeprion 300 mg ER starting in 2006.  Following this, the FDA 
conducted a pilot study consisting of a crossover with Budeprion ER 300 and Wellbutrin 
300 mg ER with 24 health individuals.  Their findings revealed that Budeprion 300 mg 
ER and Wellbutrin 300 mg ER showed differences that did not meet BE standards.  The 
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studies indicated that the mean AUC of Budeprion ER was 86% of Wellubtrin with a 
90% CI of 77-96% and the Cmax for Budeprion XL was 75% of Wellbutrin with a 90% CI 
of 65-87% (Figure 2) [62].  After these studies, Impax Labs voluntarily withdrew 
Budeprion 300 mg XL from the market.  In addition, all other manufactures were no 
longer able to sell the 300 mg ER formulations until appropriate BE studies were 
conducted at that corresponding dose.  After further review, dose-related seizures 
typically only happened in about 1 in 1000 patients and at the 450 mg dose (300 mg 
dose was considered a safe dose) [63].    
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1.9 Research Objectives 
These regulatory issues have sparked many questions about bupropion and the 
bioinequivalence issues with some of the generics at the 300 mg ER formulation.  Are 
these differences in BE due to the release mechanisms of the formulation?  Was there a 
problem with in vitro dissolution data that might have been used for extrapolation of the 
150 mg dose?  Is there a saturation of enzymes that might be occurring with a higher 
dose or region GI metabolism that might be influencing the metabolism?  What role 
dose pharmacogenomics play in terms of polymorphs in metabolism enzymes that 
might influence plasma concentrations?  Although there are probably multiple factors 
that are involved in this issue, we sought to address some of these questions, particular 
relating to metabolism, saturation of metabolic enzyme, absorption, and 
pharmacogenomics (patient variability).      
 The central hypothesis for this thesis work is that generic versions of bupropion 
have delayed release may change absorption and metabolism profiles of bupropion to 
cause bioinequivalence of controlled release bupropion drug products.   
Aim 1: Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine. 
Aim 2:  Method Development, Validation, and Sample Analysis of Bupropion HCl in 
Human Plasma. 
Aim 3:  Investigate Different Release Mechanism that May Alter Absorption, 
Metabolism, and Pharmacogenomics of Bupropion.  
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Figure 1-1.  Subcellular Fractions.  This figure depicts the subcellular fraction isolation 
from tissue for metabolism studies.   
(Adapted: http://www.xenotechllc.com/products/subcellular-fractions) 
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Figure 1-2.  Generics Failed BE Standards.  Comparing one generic, Budeprion ER 
300 to Wellbutrin ER 300, both AUC and Cmax fell out of an 80-125% using a 90% 
confidence interval. 
       
 
(Adapted from: Woodcock, J., M. Khan, and L.X. Yu, Withdrawal of generic budeprion 
for nonbioequivalence. N Engl J Med, 2012. 367(26): p. 2463-5) 
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  Chapter 2
Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine 
 
Abstract 
 Bupropion’s metabolism to form hydroxybupropion in the liver by cytochrome 
P450 2B6 (CYP2B6) has been extensively studied; however, the metabolism to form 
erythro/threohydrobupropion in the liver and intestine by carbonyl reductases (CR) 
has not been well characterized.  The purpose of this investigation was to compare 
the relative contribution of the two metabolic pathways of bupropion (by CYP2B6 and 
CR) in the subcellular fractions of liver and intestine and to identify the CRs 
responsible for erythro/threohydrobupropion formation in the liver and the intestine. 
The results showed that liver microsomes generated the highest amount of 
hydroxybupropion (Vmax= 131 pmol/min/mg, Km = 87 µM).  In addition, liver 
microsomes and S9 fractions produced similar levels of threohydrobupropion by CR 
(Vmax= 98-99 pmol/min/mg and Km =186-265 µM).  Interestingly, the liver has similar 
capability to form hydroxybupropion (by CYP2B6) and threohydrobupropion (by CR).  
In contrast, none of the intestinal fractions generated hydroxybupropion, suggesting 
that the intestine does not have fuctional CYP2B6 available for metabolism of 
bupropion. However, intestinal S9 fractions formed threohydrobupropion at 25% of 
the amount of threohydrobupropion formed by liver S9 fractions.  Enzyme inhibition 
studies and Western blots identified that the 11β-dehydrogenase isozyme 1 in liver 
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microsomal fractions was mainly responsible for the formation of 
threohydrobupropion, while AKR7 in the intestine may also be responsible for 
producing the same metabolite formation.  These quantitative comparisons of 
bupropion metabolism by CR in the liver and intestine may provide new insight on the 
efficacy and side effects of bupropion dosing.      
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Introduction 
 Bupropion is a norepinephrine/ dopamine reuptake inhibitor [1], which is 
clinically used for treatment of major depressive disorder (MDD) and smoking 
cessation [2].  Currently, over 11 million prescriptions annually of bupropion have 
been issued to over 40 million patients [3, 4].  Bupropion hydrochloride (HCl) 
extended release (ER) tablets, which is marketed as Wellbutrin XL by Biovail, has 
many generics manufacturers such as Teva/Impax, Mylan, Actavis, and Par 
Pharmaceuticals which used the current bioequivalence (BE) standard based on 
Cmax and AUC. The original approvals of the 300-mg generic bupropion HCl ER 
tablets were based on the demonstration of in vivo BE of the 150-mg generic 
bupropion HCl ER tablets to the brand name product and other in vitro criteria. 
However, a follow-up in vivo BE study on 300-mg Budeprion (bupropion HCl) ER 
tablets, manufactured by Impax Laboratories and distributed by Teva 
Pharmaceuticals, showed that the 300 mg strength failed to demonstrate BE [5]. It is 
not clear if the failure of extrapolating the BE conclusion from 150-mg to 300-mg 
tablets was related to changes of metabolism of bupropion in the liver and intestine 
between different formulations and different strengths of bupropion. Therefore, it is 
important to study in detail the bupropion metabolism mechanism in the liver and 
intestine.  
 Bupropion is rapidly (Tmax 1.3-1.9 hours) absorbed and extensively distributed 
throughout the body (Vd = 19 L/kg), and less than 1% of the parent compound is 
eliminated in urine [6, 7].  The majority of bupropion is eliminated by metabolism. It is 
well known that bupropion forms three primary metabolites: hydroxybupropion (by 
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CYP2B6) and the diastereoisomers, threohydrobupropion and erythrohydrobupropion 
(by CR) [8] (Figure 1).  Different metabolites of bupropion pose significant impact for 
its efficacy since these metabolites have 25-50% potency as compared to bupropion 
based on antidepressant screening tests in an animal model [9, 10].  In addition, the 
plasma levels of hydroxybupropion are 5-10 fold higher than the parent drug 
bupropion after oral administration of bupropion HCl [6, 9-12].  
 The metabolism of bupropion by CYP2B6 in the liver to form hydroxybupropion, 
the major metabolite of bupropion, has been extensively studied. Studies have 
shown that the kinetic formation of hydroxybupropion in liver microsome can form at 
a high extent with a Vmax ranging from 85-254 pmol/mg/min and a Km ranging from 
103-198 µM [13-15].  However, the metabolism of bupropion by CR has not been 
well characterized.  For example, what metabolic pathways (CYP2B6 and CR) play a 
more important role in the liver and intestine for bupropion metabolism? Which 
subcellular fraction in the liver and intestine are responsible for metabolism of 
bupropion? Are there any differences in how bupropion is metabolized in the liver 
and in the intestines? Which CR is responsible for bupropion metabolism in the liver 
and the intestine?  
To date, there are 11 known CR enzymes, which are categorized into two 
superfamilies: short-chain dehydrogenase/reductase (SDR) and aldo-keto reductase 
(AKR) [16, 17].  SDR family has 5 CR enzymes: CBR1, CBR3, 11 β-dehydrogenase 
isozyme 1 (11β-HSD), DHRS4, and L- Xylulose reductase.  AKR family has 6 CR 
enzymes: AKR7A2, AKR7A3, AKR1C1, AKR1C2, AKR1C3, and AKR1C4.  The 
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subcellular locations of most CR enzymes are in the cytoplasm, except for 11β-HSD 
which is localized in the microsomes [16].   
In this study we investigated the metabolism of bupropion in subcellular 
fractions (microsome, cytosolic, and S9 fractions) of the liver and intestine to 
compare the extent of formation of all three metabolites in the different subcellular 
fractions of the liver and intestine.  In addition, we conducted inhibition studies with 
these subcellular fractions to determine which CR enzymes are important for 
bupropion metabolism.   These results confirm that CYP2B6 in microsome is mainly 
responsible for hydroxybupropion.   In comparison, the liver microsome and S9 
fraction formed similar levels of threohydrobupropion by CR, which was similar to 
hydroxybupropion’s formation.  This suggests that the metabolism of bupropion by 
CYP2B6 and CR in the liver is equally important.  In contrast, none of the intestinal 
fractions detected hydroxybupropion, which suggests that the intestines didn’t 
contribute to the CYP2B6 metabolism of bupropion. Intestinal S9 fraction indeed 
generated threohydrobupropion. In fact, the formation of threohydrobupropion in the 
intestinal S9 fraction is 25% the amount that formed from liver S9 fraction.   
Furthermore, the enzyme inhibition studies and Western blotting assay suggest that 
11β-HSD is responsible for the formation of threohydrobupropion in the liver 
microsome, while ARK7 may be responsible for the same metabolite in the intestine.  
These results quantitatively compare bupropion metabolism by CR in the liver and 
intestine, which may provide new insight on its efficacy by these metabolites.     
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Materials and Methods 
Chemicals/ Reagents:  
Bupropion HCl and venlafaxine HCl (internal standard; IS) were purchased from 
Sigma (St. Louis, MO).  Hydroxybupropion was purchased from Caymen Chemicals 
(Ann Arbor, MI) and a racemic mixture of both erythrohydrobupropion and 
threohydrobupropion were purchased from Toronto Research Chemicals (Toronto, 
Canada).  β- Nicotinamide adenine dinucleotide 2’phosphate (NADPH) was also 
purchased from Sigma. Acetonitrile (HPLC grade) and methanol (HPLC grade) were 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Water was purified with a 
Milli-Q water system (Bedford, MA). Mix Gender Pooled Human microsomes, 
cytosolic and S9 fractions for both liver and intestines (duodenum and jejunum) were 
purchased from Xenotech (Lenexa, KS).  The following CR inhibitors were purchased 
from Sigma (St. Louis, MO); rutin, fluefenamic acid, and carbenozolone.  The 
following antibodies were used in the western blot; AKR1C1/2 (Abcam (Cambridge, 
England) Cat # ab131375), carbonyl reductase 1/2/3 (Santa Cruz Cat # sc-292143), 
11β-Hydroxysteroid Dehydrogenase (Type 1) (Cayman Chemical Cat # 10004303), 
AKR7A antibody (Santa Cruz Cat # sc-32944), CYP2B6 antibody (Santa Cruz Cat # 
sc-67224), Goat Anti-Mouse secondary antibody (Santa Cruz Cat # sc2005), and 
Anti-rabbit IgG antibody (Cell Signal Cat # 7074).  
 
LC-MS/MS Method 
The LC-MS/MS analysis was conducted using an Agilent 1200 HPLC system coupled 
to an API 3200 mass spectrometer (Applied Biosystems, MDS Sciex Toronto, 
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Canada) equipped with an API electrospray ionization (ESI) source. Quantitative 
analysis was accomplished on a Supelco C18 (150 x 4.6 mm I.D., 5 µm). The mobile 
phases used were purified water + 0.04% formic acid (A) and methanol + 0.04% 
formic acid (B). The LC was ran at isocratic at 35% methanol +0.04% and a flow rate 
of 0.8 mL/min.  The LC-MS/MS was operated at positive ESI ionization. The MRM 
transitions and collision energies were determined for bupropion, hydroxybupropion, 
threohydrobupropion, erythrohydrobupropion and venlafaxine. The analytical data 
was processed by Analyst software (version 1.2; Applied Biosystems, Foster City, 
CA, USA).  The quantitation of bupropion, hydroxybupropion, threohydrobupropion, 
and erythrohydrobupropion in these in vitro assay were performed by multiple 
reaction monitoring (MRM) of the [M-H]+ ion, using an internal standard (IS) to 
establish peak area ratios.  The method development was derived and optimized 
from previous studies that monitored bupropion and metabolites by HPLC or LC-
MS/MS [8, 18-20].  
Subcellular Kinetic Assay: 
Liver and intestinal microsome, cytosolic, and S9 fraction were conducted with 
concentrations of bupropion as the substrate from 1-4000 µM dissolved in PBS (3.3 
mM MgCl2 + 100 mM K2HP04+ 100 mM KH2HPO4 buffer pH=7.4) (no organic solvent 
was used in this system).  The master mix consisted of microsome, cytosolic, or S9 
fraction at a final concentration of 1 mg/mL, 4 µL of corresponding substrate, and 
PBS (3.3 mM MgCl2 + 100 mM K2HP04+ 100 mM KH2HPO4 buffer pH=7.4).  A fresh 
sample of the cofactor nicotinamide adenine dinucleotide phosphate (NADPH) was 
prepared at 16.7 mg/mL in PBS buffer.  Both master mix and NADPH was heated for 
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3 minutes at 37ºC.  Following, NADPH was added to master mix to initiate reaction.  
Sample was collected at 30 minutes; sample was spiked into ice cold methanol 
containing 500 nM of internal standard (venlafaxine).   
 
Hepatocytes Study 
Hepatocytes were ordered from Xenotech hepatosure (HCP100.H15), all reagents 
were included in kit expect for the K2500 media (50 mL).  Bupropion was added to 
cells at a final concentration of 5-1000 µM.  All reagents (tube A and B that are 
supplied with hepatocytes and K2500 media) were warmed to 37 ºC in a water bath 
for 15 minutes.  Hepatocytes were removed from liquid nitrogen and warmed in a 37 
ºC water bath for ~80 seconds.  The pellet in the hepatocyte vial was added to tube A 
and the hepatocyte vial was rinses with tube B media and added to tube A.  Tube A 
was centrifuged for 5 minutes at 100 g at 4 ºC.  The cells were re-suspended in 
K2500 media and the cell density was measured using a hemocytometer.  Cells were 
diluted so that the final concentration was 1 *10^6 cells/mL.  Using a clear 96 well 
plate, each well had 136 µL of K2500 media, 2 µL of 100X desired bupropion 
concentration, and 62 µL of cells after they were dethawed and diluted.  Reactions 
started when cells were added to each well, and were terminated at 0, 30, 60, 90, 
120 minutes by spiking 50 µL of sample into methanol with organic solvent + 500 nM 
of internal standard.  Reactions were ran in triplicate per concentration per time point.  
All samples were sonicated to break the cells and centrifuged at 15,000 rpm.  The 
supernatant was then analyzed by LC-MS/MS to quantify bupropion and metabolites 
concentration.   
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Carbonyl Reductase Inhibition Study 
For inhibition studies, bupropion substrate was used at the corresponding Km for 
threohydrobupropion (since this was the dominant metabolite formed by CR) 
determined from the subcellular kinetic analysis (liver microsome = 186 µM, liver S9 
= 265 µM, liver cytosolic = 90 µM, intestinal microsome = 150 µM, intestinal cytosolic 
= 5.6 µM, and intestinal S9 = 573 µM).  The master mix consisted of microsome, 
cytosolic, or S9 at a final concentration of 1 mg/mL, bupropion, PBS (3.3 mM MgCl2 
+ 100 mM potassium phosphate buffer pH=7.4), and CR inhibitor at 3 fold higher 
than the IC50 (the 3XIC50 values were; rutin 6.1 µM, flufenamic acid 60 µM, and 
carbenoxolone 250 nM).  A fresh sample of the cofactor NADPH was prepared at 
16.7 mg/mL in PBS buffer.  Both master mix and NADPH was heated for 3 minutes at 
37ºC.  Following, NADPH was added to master mix to initiate reaction.  Sample was 
collected at 0, 30, 60, and 90 minutes; sample was spiked into ice cold methanol 
containing 500 nM of internal standard (venlafaxine). 
 
Standards and Sample Preparation 
Stock solutions of bupropion, hydroxybupropion, threohydrobupropion, or 
erythrohydrobupropion at 2 mg/mL were prepared in methanol to generate a working 
solution of 100 µg/mL.  An aliquot of this solution was diluted in 1(MeOH):1(Milli-Q 
water) to get a series of working standard solutions of 5, 10, 25, 50, 100, 250, 500, 
1000, 2500, and 5000 ng/mL.  Internal standard (IS) solution was prepared by 
diluting the stock solution of venlafaxine to yield a final concentration of 500 nM in 
1(MeOH):1(Milli-Q water).  After preparation of working standards, 50 µL of the 
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appropriate concentrations of analyte was added to 150 µL of IS solution (500 nM of 
venlafaxine in in 1(MeOH):1(Milli-Q water)), and 50 µL of PBS.   Fifty µL of sample 
from microsome, cytosolic, or S9 reaction at each time point was spiked into 150 µL 
of IS solution (500 nM of venlafaxine in in 1(MeOH):1(Milli-Q water)) and 50 µL 
1(MeOH):1(Milli-Q water).  Samples were vortex for 1 min, followed by centrifugation 
for 15 min at 14,000 rpm in an Eppendorf centrifuge. The supernatant was transfer to 
vials and 5 µl was injected for LC-MS/MS analysis. 
 
Western Blot 
Subcellular fraction; liver and intestinal microsome, S9, and cytosolic fractions were 
lysed using radioimmunoprecipitation assay buffer ((RIPA: 50 mM Tris-HCL, 150 mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS, pH 7.4± 0.2) (Boston 
BioProducts, BP-115)) with 1% protease inhibitor and 1% EDTA.  Approximately 200 µL 
of RIPA buffer was used to resuspend each subcellular fraction which was incubated on 
ice for 30 minutes.  Following, each sample was centrifuged at 14,000 rpm for 15 
minutes at 4ºC.  The protein concentration of the supernatant of each sample was 
quantified using Pierce BCA Protein Assay Kit (23225).  All samples were diluted to 
have a protein concentration of 750 µg/mL.  Laemmli sample buffer (BIO-RAD 161-
0737) was used according to protocol; mix 950 µL of sample buffer with 50 µL of β-
mercaptoethanol. Each sample was prepped by using 50 µL of protein sample with 25 
µL of sample buffer and boiled samples at 95 ºC for 10 minutes.  All samples were 
loaded on an SDS-PAGE gel (25 µL) and ran at 200 V for about 2 hours.  The ladder 
see-blue (Life Technologies LC5625) was used to determine the proteins molecular 
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weight.  The running buffer for the SDS-Page gel consist of 3.0 g of tris base, 14.4 g of 
glycine, and 1 g of SDS with ddH20 to 1 L.  A wet transfer was performed using transfer 
buffer (3.03 g of tris base, glycine 14.4 g, 200 µL of methanol, and ddH20 to 1 L).  The 
transfer was done using a PVDF immune-blot membrane (BIO-RAD 162-0177) at 250 
mV for 3 hours.  The membrane was blocked for 1.5 hours using 5% of milk in Tris-
Buffered Saline and Tween 20 (TBST buffer) (TBST buffer: 2.4 g of tris, 8 g of NaCl 
adjust pH to 7.6 with HCl, 0.1% tween 20 (v/v), and 1L of ddH2O).  Primary antibody 
was added to membrane at various dilutions according to manufacturer’s protocol; 
AKR1C1/2 antibody (dilution 1:500), CRB1/2/3 (dilution 1:500), 11β hydroxysteroid 
dehydrogenase (dilution 1:200), AKR7 (dilution 1:200), and CYP2B6 (1:200) (dilutions 
were used as suggested by manufactures) and incubated at 4ºC overnight.  Membrane 
was washed with TBST (3X) before the corresponding secondary antibody was added; 
AKR1C1/2 (dilution 1:2000), CRB1/2/3 (dilution 1:2000), 11β hydroxysteroid 
dehydrogenase (dilution 1:5000), AKR7 (dilution 1:5000), and CYP2B6 (dilution 1:5000) 
for 1.5 hours at room temperature.  The membrane was washed again with TBST (3X).  
Stripping buffer (Thermo Scientific 21059) was used to remove previous antibody, we 
confirmed that the antibody was washed out each time.  Proteins were detected using 
X-ray development; 5 mL of substrate (2.5 mL of reagent 1 and 2.5 mL of reagent 2) 
was added to the membrane before detection (thermo cat #’s 1859701 and 1859698).    
 
Data Analysis 
For microsome, cytosolic, and S9 kinetics, all data was converted into pmol/min/mg 
and plotted against concentration of bupropion.  Graphpad Prism5 was used to 
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simulate the Km and Vmax using the Michaelis-Menten model using the following 
equation. 
(1) 
𝑌 =
𝑉𝑚𝑎𝑥 ∗ [𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒]
(𝐾𝑚 + [𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒])
 
The intrinisic cleareance for S9 formation of each metabolite was calculated using the 
following equation.  
(2) 
𝐶𝐿𝑖𝑛𝑡 = (
𝑉𝑚𝑎𝑥
𝐾𝑚
) 
 For statistical analysis, R version 3.0.3 was ran with a t-test.    
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Results 
LC-MS/MS development for bupropion and metabolites 
An LC-MS/MS method was developed in order to quantify bupropion, 
hydroxybupropion, erythrohydrobupropion, and threohydrobupropion.  Since the 
fragmentations of the diastereoisomers (threohydrobupropion and 
erythrohydrobupropion) are the same and bupropion also had very similar 
fragmentation, it was necessary for all analytes to be separated by LC.  Figure 2A 
shows the MRM chromatograms of the successful separation of all analytes.  The MS 
parameters are highlighted in figure 2B for each analyte. 
Calibration curves for each analyte were performed in order to quantify 
samples in later studies.  A wide linear range was achieved for each analyte (figure 
2C).  In addition, the coefficient of determination for each analyte was greater than or 
equal to 0.99.  The lower limit of detection was either 5 or 10 ng/mL (noted in figure 
2C) depending on which analyte was being monitored.  
Metabolism in Liver Subcellular fractions 
To begin with, we used liver microsome, cytosolic, and S9 fractions to look at 
bupropion’s metabolism.  Bupropion was used as the substrate at concentrations 
ranging from 1-4000 µM.  Samples were analyzed by LC-MS/MS to establish the 
kinetics, and bupropion, hydroxybupropion, threohydrobupropion, and 
erythrohydrobupropion were monitored.  Figure 3A-C shows the formation of 
hydroxybupropion in liver microsome, S9 fraction, and cytosolic fraction respectively.  
Hydroxybupropion was formed at the highest extent in liver microsome (Km = 87.98 ± 
 
 
35 
 
20.2 µM and Vmax = 131.2 ± 5.6 pmol/min/mg), which was expected since 
microsomes typically contain concentrated amounts of CYP’s.  In the S9 fraction, 
hydroxybupropion formation was still apparent but the formation occurred at a lower 
of extent (Km = 99.53 ±18.91 µM and Vmax = 51.45 ± 1.9 pmol/min/mg).  
Hydroxybupropion formation in the cytosolic fraction was almost negligible (Km = 
71.35 ± 127 µM and Vmax = 1.594 ± 0.52 pmol/min/mg).  These results suggest that 
CYP enzymes which are subcellularly localized in microsomes are responsible for the 
formation of hydroxybupropion in the liver. 
Threohydrobupropion was also formed in all subcellular liver fractions (Figure 4A-
C).  The extent of formation in both microsome and S9 fractions were about the 
same; however, the affinity differed slightly (microsome: Km = 186.3 ± 53.48 µM and 
Vmax = 98.37 ± 6.6 pmol/min/mg; S9: Km = 265.7 ± 77.79 µM and Vmax = 99 ±7.5 
pmol/min/mg).  In the cytosolic fraction, threohydrobupropion was formed at a lesser 
extent (Vmax: 14.56 ± 0.714 pmol/min/mg and Km: 89.82 ± 22 µM).  These results 
suggested that the CR enzyme which is subcellularly localized in the microsomes, 
11β hydroxysteroid dehydrogenase, plays a major role in the conversion of bupropion 
to threohydrobupropion.  In addition, since the cytosolic fraction still forms 
threohydrobupropion to some extent, this suggested there may be multiple CR 
enzymes responsible for this metabolism.   
Finally, we saw that erythrohydrobupropion was also formed in liver microsome, 
S9, and cytosolic fractions (figure 5A-C, respectively); however, the extent of 
formation was very small in all subcellular fractions (microsome: Km = 41.45 ± 26.62 
µM and Vmax = 2.649 ± 0.3 pmol/min/mg; cytosolic: Km=
 274.4 ± 254 µM and Vmax = 
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3.654± 1.2 pmol/min/mg; S9: Km = 107 ± 32.14 µM and Vmax = 4.23 ± 0.286 
pmol/min/mg).  These results suggest that hydroxybupropion and 
threohydrobupropion is the dominant metabolite in the liver subcellular fraction.  Yet, 
similar to threohydrobupropion, since formation of erythrohydrobupropion occurred in 
both the microsome and cytosolic fractions, this again suggested that multiple CR 
enzymes may be involved in erythrohydrobupropion’s formation. A summary of the 
liver kinetics are summarized in table 1A.   
 Using the Michaelis-Menten kinetic parameters (Vmax and Km) we were able to 
calculate the intrinsic clearance for each metabolite using the S9 fraction (since this 
contains both microsome and cytosolic fractions) in the liver (Table 2). After adding 
each metabolite intrinsic clearance, we calculated the liver contributes a CLint of 
931.8 µL/min/mg.  
Metabolism in Intestinal Subcellular fractions 
We continued to evaluate the metabolism of bupropion using intestinal 
microsome, cytosolic, and S9 fractions.  Similar to the liver metabolism, we used 
bupropion at concentrations from 1-4000 µM and analyzed samples by LC-MS/MS to 
establish the kinetics of hydroxybupropion, erythrohydrobupropion, and 
threohydrobupropion.  However, unlike the liver fractions where all metabolites were 
detected, the only metabolite that formed through the intestinal metabolism was 
threohydrobupropion.  Both hydroxybupropion and erythrohydrobupropion were 
undetectable in both intestinal microsome, cytosolic, and S9 fraction.  This suggested 
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that CYP2B6 metabolism does not occur in the intestines since hydroxybupropion 
was unable to form.  
The extent in which threohydrobupropion was formed was smaller compared to its 
formation in the liver (figure 6 A-C) (microsome: Km = 149.9 ± 28.8 µM and Vmax = 
5.55 ±0.4 pmol/min/mg; cytosolic: Km = 569 ± 64.89 µM and Vmax = 5.649 ± 0.214 
pmol/min/mg and S9: Km = 573.4 ± 188.9 µM and Vmax = 25.87 ± 2.8 pmol/min/mg).  
The formation of threohydrobupropion was 25% of the formation that which occurred 
in the liver S9 fraction.  Similar to the formation in the liver, these data suggest that 
multiple CR enzymes are involved in the formation of this metabolite. A summary of 
the intestinal S9 kinetics formation of each metabolite is summarized in Table 1B.  
Similarly to the liver, using the Michaelis-Menten kinetic parameters (Vmax and Km) 
we were able to calculate the intrinsic clearance for threohydrobupropion using the 
S9 fraction in the intestines (Table 2).  This was about 20 fold lower than the liver 
CLint clearance since two of the metabolites did not form in the intestines and 
threohydrobupropion formations was 25% of the formation in the liver S9 fraction.  
Nevertheless, the CLint in the intestines S9 fraction was estimated to be 45 µl/min/mg.   
Metabolite inhibition by Carbonyl Reductase Inhibitors  
Next we went on to evaluate which CR enzymes are important for the reduction of 
bupropion and whether there might be multiple enzymes involved in this process.  
Using the microsome, cytosolic, and S9 fraction assay, we added various CR 
inhibitors and analyzed the reduction of metabolite formation.  The inhibitors that 
were chosen were the following: rutin, which has been shown to target the CRB 
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family of CR at an IC50 of 2.1 µM; flufenamic acid, which has been reported to inhibit 
AKR family 67% at concentrations of 20 µM; and carbenoxolone, which targets the 
microsomal CR 11β hydroxysteroid dehydrogenase at an IC50 values in the nM range 
[21-23].  We monitored all metabolite formation with each inhibitor and compared 
these results to a control with no inhibitor.   
For the formation of hydroxybupropion, none of the three inhibitors had a 
significant effect compared to control on any liver subcellular fraction (figure 7A), as 
expected since formation of this metabolite occurs via CYP2B6.  In addition, this 
metabolite was again not detected in any intestinal fraction.  These results suggested 
no CRs are involved in formation of hydroxybupropion.   
However, for threohydrobupropion formation, inhibition was observed in both the 
liver and intestinal subcellular fractions.  In the liver, carbenoxolone, the inhibitor of 
11β hydroxysteroid dehydrogenase, showed as much as 82.4% inhibition compared 
to control in the liver microsome.  Flufenamic acid was shown to have about a 40% 
inhibition on threohydrobupropion formation in liver cytosolic fraction (Figure 7B).  
These results suggested that in the liver, 11β hydroxysteroid dehydrogenase was the 
dominant enzyme in the liver for reduction of bupropion to threohydrobupropion.   
However, in the intestinal subcellular fractions, carbenozolone seemed to have no 
significant effect on inhibiting threohydrobupropion formation.  Furthermore, 
flufenamic acid showed inhibition on intestinal fractions ranging from 57.8-78.7% of 
threohydrobupropion formation (Figure 7B).  Minor inhibition was seen with rutin, 
implicating minor involvement of the CRB family of CR enzymes in the formation of 
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threohydrobupropion.  All together, the liver and intestinal data for the formation of 
threohydrobupropion suggest that both 11β hydroxysteroid dehydrogenase and the 
AKR family of CR enzymes are the major CR enzymes responsible for 
threohydrobupropion formation.   
In the same way, erythrohydrobupropion formation was inhibited by both 
carbenoxolone and flufenamic acid (Figure 7C).  Carbenoxolone inhibited the 
formation of erythrohydrobupropion by 95% in liver microsome and 91.6% in liver S9 
fraction yet had no effect on liver cytosolic fraction.   Flufenamic acid showed about 
67-88% inhibition in the liver S9 and cytosolic fractions.  These results suggested that 
11β hydroxysteroid dehydrogenase and AKR family are the dominant enzymes that 
form erythrohydrobupropion in the liver.      
Hepatocyte Kinetics 
 We measured the kinetics of the metabolite formation using hepatocytes.  
Hepatocytes have scaling factors that can translate into CL hepatic unlike S9 fraction.  
We were only able to detect the formation of hydroxybupropion and 
threohydrobupropion using hepatocytes, no erythrohydrobupropion was able to be 
detected (supplemental figure 1).  The affinity for both hydroxybupropion and 
threohydrobupropion were both much higher than previous in vitro systems used.  
Supplemental table 1A shows that the CLint calculated from the hepatocytes kinetics.  
A previous paper showed that the conversion between cell to kg can calculate by 
99*10^6 cell/ gram of liver and 21 gram liver/ kg of body weight [24].  Using this we 
scaled the intrinsic clearance to in vivo, 45.67 mL/min/kg supplemental table 1B.  
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Finally, we showed that the hepatic clearance was 5.4 mL/min/kg (supplemental 1C) 
assuming fraction unbound is 0.16 and the human blood flow is 20.7 ml/min/kg.       
Western Blot 
 Finally, we went on to confirm whether these enzymes of various CR enzymes 
are expressed in the different subcellular fraction.  Analysis of protein expression was 
performed using an immunoblot after separation by SDS-Page gel (Figure 8).  Both 
liver and intestinal microsome, cytosolic, and S9 fraction was examined for CYP2B6, 
11β hydroxysteroid dehydrogenase, CRB1/2/3, AKR7 family, and AKR1A family.   
It was observed that CYP2B6 was primarily only expressed in liver microsome 
with minor expression in the liver S9 fraction (lane 1 & 2).  CYP2B6 was absent in 
liver cytosolic (lane 3) and all intestinal fractions (lane 4-6).  This is consistent with 
the metabolite formation data suggested that hydroxybupropion predominantly 
formed in liver microsome and S9 and does not participate in intestinal metabolism of 
bupropion.  11β hydroxysteroid dehydrogenase was highly expressed in liver 
microsome and S9 fraction (lanes 1 & 2); its expression in the intestines was almost 
non-existing, supporting our results with the inhibition datathat 11β hydroxysteroid 
dehydrogenase activity is dominant in the liver.  The CRB1/2/3 enzymes were 
primarily found to be expressed in both liver and intestinal S9 and cytosolic fractions 
(lanes 2, 3, 5, 6); however, these enzymes may not be important in bupropion’s 
metabolism, as suggested by the inhibition data.  The AKR1A family had very little 
expression in any of the subcellular fractions except minor expression in liver S9 and 
liver cytosolic (lanes 2 & 3).  Finally, the AKR7 family enzymes were found to be 
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expressed in all subcellular fractions.  This supported the CR inhibition data seen by 
flufenamic acid in both liver and intestines.  All together, the enzyme expression data 
verified the results seen in the formation and inhibition studies as those enzymes 
were expressed in the corresponding subcellular fraction.   
Discussion 
In our studies, we show that the contribution of hydroxybupropion and 
threohydrobupropion formation in the liver (microsome and S9 fractions) occur at 
similar levels.  In addition, we showed that no CYP2B6 expression or metabolism to 
form hydroxybupropion in the intestines occurs.  However, the only metabolite that 
forms in the intestines is threohydrobupropion. Its formation in the intestinal S9 
fraction is 25% of that seen in the liver S9 fraction.  Furthermore, inhibition studies 
prove that there are multiple CR enzymes that are involved in the metabolism of 
bupropion to threohydrobupropion; and the CR activity may have a gastrointestinal 
(GI) regional dependency which influences the metabolism of the parent compound.  
Western blots confirmed that the CR enzymes important for metabolizing bupropion 
are expressed in the corresponding subcellular fractions.    
Previous studies have shown that CYP450 2B6 metabolism of bupropion forms 
hydroxybupropion [13, 25-28].  In addition, studies have also suggested that other 
CYPs such as CYP2C19, CYP2E1, and CYP3A4 might have a minor roles in the 
hydroxybupropion formation but still need to be confirmed [29].  Therefore, based off 
of liver microsome stability assays, it was thought that hydroxybupropion was the 
major metabolite.  Several studies failed to realize that the CR pathway to form 
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threohydrobupropion and erythrohydrobupropion may not occur extensively in liver 
microsomes since most of these enzymes are subcellularly located within the cytosol 
[13, 30].   
Therefore, examining all subcellular fractions; microsome, cytosolic, and S9 
fraction will help to explain more broadly which enzymes are responsible for 
bupropion’s metabolism and at what rate these metabolites are formed.  Typically, 
CYP enzymes are localized in the microsomes.  On the other hand, most other CR 
are subcellularly located in cytosolic fractions, expect for 11β-HSD, one of the only 
CR enzymes that is subcellularly localized in microsomes.  Using an S9 fraction, 
which contains both cytosolic and microsomes, allowed us to compare metabolite 
formations across the three metabolites.  We found that in the S9 fractions 
threohydrobupropion has a 2-fold higher formation compared to hydroxybupropion 
suggesting that many CR enzymes have been under looked for bupropion’s 
metabolism  Although hydroxybupropion formation in microsomes is slightly higher 
than S9 fraction, this difference in activity between microsome and S9 fraction is 
normal since microsomes are concentrated CYP, where S9 fraction contain both 
CYP and cytosolic fraction [31, 32].      
In Molnari et al [14], the authors found that threohydrobupropion was the major 
metabolite in liver microsome, which disagrees with many previous studies that 
identified hydroxybupropion as the major metabolite and the results presented here.  
Although, in our studies, threohydrobupropion was the major metabolite formed in 
liver S9 fraction, hydroxybupropion still forms at the highest extent in liver 
microsomes.  Moreover, the authors saw no change with flufenamic acid in inhibition 
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studies in the liver where we did.  However, this inhibitor seemed to have a larger 
effect on intestinal fraction, which was not pursued in the Molnari study.    Likewise, 
in Meyers et al. 2013 [30] the authors showed the 11 β-HSD was the CR enzyme 
important for metabolizing bupropion to form threohydrobupropion.  While our data 
agrees with this, a more thorough analysis of subcellular fractions could have been 
explored.  In this study, the authors only examine liver microsomes and in which case 
only 11 β-HSD activity would be observed.  Therefore, cytosolic fractions were 
needed to be examined to see if there were multiple CR enzymes that contribute to 
bupropion metabolism.   
 Our results suggest that both hydroxybupropion and threohydrobupropion are 
important metabolites to consider for the metabolism of bupropion.  This is consistent 
with in vivo studies which looked at the pharmacokinetic levels of bupropion and 
metabolites and that both hydroxybupropion and threohydrobupropion showed higher 
plasma concentration than the parent drug, bupropion (erythrohydrobupropion 
concentration was minor or undetectable) [33].  In addition, this is consistent with our 
hepatocyte studies.  Although are CL hepatic is a little overestimated considered the 
reported CL total is 36 mL/min/kg whereas our CL hepatic was 45.6 mL/hr/kg.  It has 
been noted that is common to over or under estimate CL hepatic using in vitro systems 
compare to the true in vivo hepatic clearance [34]. 
To the best of our knowledge, no authors have studied the formation of 
bupropion’s metabolites in any intestinal fractions.  The intestines have been shown 
to be involved in both phase I and phase II metabolism, which might influence the 
metabolism of bupropion.  Although CYP enzyme expression is typically less in the 
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intestines compared to the liver (20 pmol/mg of microsome compared to 300 
pmol/mg of microsome) [35], metabolism in this region of the GI tract should still be 
investigated.  Likewise, the expression of CR enzymes has been found to be highly 
concentrated in both liver and small intestines [35, 36].  We did not observe any 
hydroxybupropion (CYP2B6 metabolism) in the intestines, this finding is consistent 
with another study that looked for various CYP expression in intestinal microsomes 
and similarly saw no CYP2B6 present [37].  However, in this study 
threohydrobupropion metabolized by CR was able to form in all three subcellular 
intestinal fractions (microsome, S9, and cytosolic) again showing how studies have 
discounted the CR pathway for metabolism of bupropion.  The intestinal subcellular 
fractions used in these studies were taken from the duodenum and jejunum.  The 
intestinal metabolism is an important concept to understand since these metabolites 
are active.  One hypothesis for the failure of extrapolating BE from lower strength to 
higher strength, as discussed in the introduction, could be that we have discounted 
the CR metabolism particularly in the intestines and these enzymes were saturating.  
However, a more thorough analysis would be needed to disapprove/approve the 
hypothesis and this is also true in vivo.     
In conclusion, these results suggest that depending on the subcellular 
localization of the bupropion and tissue type, the metabolism can be different forming 
different metabolites by multiple enzymes (both CYP and CR).     
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Figure 2-1.  Bupropion and Metabolism. Bupropion is metabolized by Cytochrome 
P450 2B6 to form hydroxybupropion and by Carbonyl Reductase to form the 
diasterisomers, threohydrobupropion and erythrohydrobupropion. 
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Figure 2-2.  Method Development for Bupropion and Metabolites.  (A) Separation of 
Bupropion and metabolite for detections using LC-MS/MS. (B) LC/MS parameters for 
bupropion and metabolites.  (C) Validation with Standards for bupropion and 
metabolites.  All analytes had a good linear range with acceptable coefficient of 
determination. CE: collision energy, DP: declustering potential, EP: entrance potential, 
CXP: collision cell exit potential. 
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Figure 2-3.  Hydroxybupropion Metabolite Formation in Liver Subcellular 
Fractions.  Hydroxybupropion formation is indicated in Liver Microsome and Liver S9.  
No formation occurred in Liver Cytosolic. Data are presented as mean ± S.D. (n = 3). 
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Figure 2-4.  Threohydrobupropion Metabolite Formation in Liver Subcellular 
Fractions.  Threohydrobupropion formation is indicated in Liver Microsome, Liver S9, 
and Liver Cytosolic. Data are presented as mean ± S.D. (n = 3). 
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Figure 2-5.  Erythrohydrobupropion Metabolite Formation in Liver Subcellular 
Fractions.  Erythohydrobupropion formation is indicated in Liver Microsome, Liver S9, 
and Liver Cytosolic. Data are presented as mean ± S.D. (n = 3). 
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Figure 2-6.  Threohydrobupropion Metabolite Formation in Intestinal Subcellular 
Fractions.  Threohydrobupropion formatation is indicated in Intestinal Microsome, 
Intestinal S9, and Intestinal Cytosolic. Data are presented as mean ± S.D. (n = 3). 
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Figure 2-7. Threohydrobupropion Metabolite Formation in Intestinal Subcellular 
Fractions.  Threohydrobupropion formatation is indicated in (A) Intestinal Microsome  
(B) Intestinal S9 (C) Intestinal Cytosolic. Data are presented as mean ± S.D. (n = 3). 
*P<0.05, **P<0.01. 
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Figure 2-8. Enzyme Expression in Human Subcellular Fractions.  Subceullar 
fractions were ran on an SDS-polyacrylamide gradient (4-12% W/V) gel to detect 
various carbonyl reductase enzyme and CYP2B6.  Lane 1: Liver Microsome (LM).  Lane 
2: Liver S9 (LS9). Lane 3: Liver Cytosolic (LC).  Lane 4: Intestinal Microsome (IM).  
Lane 5: Intestinal S9 (IS9).  Lane 3: Intestinal Cytosolic (IC). 
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Table 2-1. Summary of Subcellular Kinetics.  (A) The Vmax and Km are highlighted 
for each metabolite in liver microsome, S9, and cytosolic fraction.  (B) The Vmax and 
Km are highlighted for threohydrobupropion metabolite in lintestinal microsome, S9, and 
cytosolic fraction.  If no metabolite formation occurred in the corresponding fraction, this 
was denoted by NF. HBUP: hydroxybupropion, TBUP:threohydrobupropion, EBUP: 
erythrohydrobupropion. 
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Table 2-2.  Estimated Intrinsic Clearance. Using equation (2) the intrinsic clearance 
for both liver and intestines  S9 fraction was calculated based off the Michaelis Menten 
equation assuming the linear portion of the curve.  The relative contribution for each 
metabolite in S9 liver or intestines is indicated in the table.   
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Supplemental Figure 2-1.. Hepatocytes Kinetics.  The formation of (A) 
hydroxybupropion and (B) threohydrobupropion were measured using hepatocytes at 
concentrations of bupropion from 5-1000 µM.  Data are presendted as mean ± S.D. 
(n=3).   
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Supplemental Table 2-1.  Hepatocytes Kinetics Summary.  (A) Represents the 
instrinic clearance calculated based on the hepatocyte kinetics, using equation 1 
(Vmax/Km).  Assuming Scaling factors shown above (Barter 2007) data was scaled to 
in vivo CL intrinsic clearance (B).  (C) Represents the hepatic CL and extraction ratio.   
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  Chapter 3
Method Development, Validation, and Sample Analysis of Bupropion in Human 
Plasma. 
 
Abstract 
A liquid chromatography tandem with electrospray ionization mass spectrometry 
method was developed to quantify bupropion and the major metabolites 
(hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human 
plasma. The analytes were extracting from the plasma using protein precipitation (main 
steps include addition of organic solvent (methanol), vortex, centrifugation, and analysis 
of supernatant by LC-MS/MS).  The analytes were separated using a C18 Supelco 
column with an isocratic gradient at 35% methanol and 65% water (0.04% formic acid, 
v/v) for 17 minutes.  Method development and validation was performed to ensure that 
the analytical procedure was appropriate for detection of bupropion and metabolites in 
plasma.  After method validation met the standards of  the FDA suggested Bioanalytical 
Methods Guidelines, samples obtained from the clinical trial were analyzed to quantify 
the concentration of bupropion and major metabolites in plasma samples over 96 hours.   
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Introduction 
Bupropion HCl is a clinically available drug product that was first marketed as 
Wellbutrin in the 1980’s as an immediate release product.  Bupropion is used for major 
depressive disorder, smoking cessation, and seasonal depression.  Over the last 25 
years, various formulations have come to market (including a sustained and an 
extended release) in addition to generic bupropion products [1-3].  All generic products 
undergo bioequivalent (BE) testing to show that using a 90% confidence interval; the 
mean of both the rate (Cmax) and extent (Area Under the Curve (AUC)) of the test and 
reference are within 80-125% [4].  Many generics for bupropion were approved from 
doses of 75-300 mg in 3 formulations.  Due to dose related seizures, the BE studies for 
the extended release (ER) 300 mg, data was extrapolated using the results from the 
150 mg BE study.  Both the 150 mg and 300 mg ER for generics were approved for 
market.   However, after addition studies, several generic products at the 300 mg dose 
failed to meet BE standards [5].  This has then sparked many questions trying to 
understand what is causing the difference in systemic exposure for both bupropion and 
metabolites.  Bupropion is also extensively metabolized (as the primary route of 
elimination) to form three primary active metabolites; hydroxybupropion, 
threohydrobupropion, and erythrohydrobupropion [6, 7].  In an animal model it was 
shown that these metabolites may exhibit 25-50% potency [8, 9]. Although many in vitro 
studies have been perform to quantify the formation rate of these metabolites [7, 10-12], 
it is unknown if these active metabolites are causing any difference in efficacy.  In 
addition, another question is whether gastrointestinal (GI) regional dependency might 
affect the absorption and/or metabolism of bupropion? 
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Therefore, a clinical study was designed to address some of these questions by 
running a single dose, 6 phase, crossover study (immediate release 75 & 100, 
sustained release 100 &150, and extended release 150 & 300 mg).  The plasma from 
these samples were analyzed using liquid chromatography- mass spectrometry/ mass 
spectrometry (LC-MS/MS)  The purpose of the following studies were to develop a 
sensitive, specific, and reproducible analytic method using LC-MS/MS to detect 
bupropion and it’s major metabolites (hydroxybupropion, threohydrobupropion, and 
erythrohydrobupropion) in human plasma.   
After the method was developed, we confirmed that the matrix effect had little 
influence on detection of bupropion and metabolites, our samples had less than 10% 
difference when comparing neat (organic solvent) to plasma samples.  We also showed 
that the accuracy and precision for both inter- and intra-day was within 85-115% and 
%CV was less than 15% of the nominal concentration, respectively.  There was very 
little carry over for all analytes including the internal standard (<0.1%) and the recovery 
was reproducible.  Finally, we showed the samples were stable at room temperature 
(25º C) for up to 16 hours.  The bioanalytical method was developed based off 
Guidance for Industry: Bioanalytical Method Validation [13]. Following method 
validation, clinical samples were analyzed trying to unravel some of the issues that may 
be causing bioinequivalence for bupropion.   
Materials/ Methods 
Reagents 
Bupropion HCl, venlafaxine HCl (internal standard; IS), and formic acid were purchased 
from Sigma (St. Louis, MO).  Metabolites; hydroxybupropion was purchased from 
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Caymen Chemicals and both erythrohydrobupropion and threohydrobupropion were 
purchased from Toronto Research Chemicals.  Methanol (HPLC grade) were purchased 
from Fisher Scientific (Pittsburgh, PA, USA).  Water was purified with a Milli-Q water 
system (Bedford, MA). All other solvents and chemicals were analytical grade or better.  
 
Liquid Chromatography/ Mass Spectrometry-Mass Spectrometry Optimization 
The LC-MS/MS analysis was conducted using an Agilent 1200 HPLC system coupled to 
an API 3200 mass spectrometer (Applied Biosystems, MDS Sciex Toronto, Canada) 
equipped with an API electrospray ionization (ESI) source. Quantitative analysis was 
accomplished on a Supelco C18 (150 x 4.6 mm I.D., 5 µm). The mobile phases were 
0.04% formic acid in purified water (A) and 0.04% formic acid in methanol (B). An 
isocratic was held constant at 35% and the flow rate was set at 0.8 mL/min for 17 
minutes. 
The LC-MS/MS was operated at positive ESI ionization.  The MRM transitions and 
collision energies determined for bupropion, hydroxybupropion, threo/ 
erythrohydrobupropion and internal standard are listed in Table 1. The source 
parameters for the MS consisted of a curtain gas (CUR) of 45, collision gas (CAD) at 
medium, ionspray voltage at 5500, temperature (TEM) was 700, ion source gas (GS1 
and GS2) were both 70 for bupropion and metabolites. The analytical data were 
processed by Analyst software (version 1.2; Applied Biosystems, Foster City, CA, USA). 
The quantitation of bupropion, hydroxybupropion, threohydrobupropion and 
erythrohydrobupropion were performed by multiple reaction monitoring (MRM) of the 
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[M-H] + ion, using an internal standard (IS) to establish peak area ratios. The LC-MS/MS 
method was adapted and slightly modified from other studies [6, 14, 15]. 
 
Stock Solutions and Sample Prep  
Bupropion, hydroxybupropion, threohydrobupropion, and erythrohydrobupropion  
solutions were made fresh at least every two weeks.  All 4 compounds were dissolved 
in methanol at 2 mg/mL.  Stock solutions for the standard curves were made at 10 
µg/mL.      
 
All samples contained 500 nM of internal standard in methanol (unless noted).  Typical 
standard preparation consisted of 150 µL of internal standard, 50 µL of plasma, and 50 
µL of methanol (if this was not a clinical sample or blank, analyte was dissolved in this 
methanol at the appropriate concentration).  After all samples were vortex for at least 
one minute, centrifuged at 14,000 rpm, and the supernatant was transferred to an 
amber color HPLC vial for analysis on the LC-MS/MS.   
Results 
Method Development Selectivity & Specificity 
In order to evaluate the selectivity, blank plasma samples were ran (n=3) to ensure no 
excess background signal was detected (Figure 1).  The average noise was 50 CPS.  
This was done using 200 µL of methanol and 50 µL of plasma.  In addition, we looked at 
specificity by looking at the internal standard alone (n=3) in the plasma matrix (Figure 
2).  There was no interference observed and the retention time was consistent.  To 
evaluate the specificity for each analyte; bupropion, hydroxybupropion, 
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threohydrobupropion, or erythrohydrobupropion were ran at the corresponding LLOQ 
(n=3/ analyte) (Figure 3).  For each LLOQ we ensured that the signal to noise (S/N) 
ratio was greater than 3.5 and the peak area for the LLOQ was at least 5 times the peak 
area of the blank sample.   
Calibration Curves 
In order to quantify bupropion and its metabolites from the plasma samples obtained in 
our clinical trial, we developed calibration curves for each analyte.  Table 2 shows the 
linear range, linear equation, coefficient of determination (R2), and LLOQ for each 
analyte.  Calibration curves consisted of at least 6 non- zero samples that covered the 
linear range.  The accuracy of the nominal concentration for each calibration curve 
sample was within 80-120% and the R2 for each curve was above .99 for each batch.  
With each batch of clinical samples analyzed, a fresh calibration curve for each analyte 
was made and quality control (QC) samples at low (10ng/mL), medium (50 ng/mL), and 
high (2500 ng/mL) concentrations were used to validate the standard curves (two QC 
per concentration per analyte).  The QC needed to be within 85-115% of nominal 
concentration with the exception of the LLOQ which was within 80-120%.  At least 67% 
(4/6) of QC samples needed to meet these criteria for it to be an acceptable run.    
Matrix Effect 
In order to examine whether the matrix had an effect on the detection signal, we 
prepared samples in both plasma and organic solvent (neat).  Each sample had 150 µL 
of methanol containing internal standard (500 nM), 50 µL of sample at desired 
concentration (10, 500, 2500 ng/mL), and 50 µL of plasma or methanol (neat).  All 
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samples were vortex, centrifuged at 14,000 rpm, and the supernatant was transferred to 
an amber HPLC vial.  In order to determine the matrix effect, the peak area ratio of the 
neat vs plasma sample was compared and was acceptable if the %CV was less than 
15% of nominal concentration.  Table 3 showed that the plasma matrix had very little to 
no effect on quantifying analytes in each sample.  
Accuracy/ Precision 
At three different concentrations (10, 500, 2500 ng/mL) (n=5) for each day, the precision 
and accuracy was measured.  Samples were prepared as normal by protein 
precipitation.  The intra- and inter- day accuracy and precision was also evaluated.  
Each day we ran 5 samples per analyte for 3 days.  The accuracy was within 15% of the 
nominal value and the precision had a %CV less than 15%.  Tables 4 & 5 shows that 
the method met acceptable criteria for both accuracy and precision.   
Recovery 
Using 3 different batches and 3 different concentrations (10, 500, 2500 ng/mL) for each 
analyte, the recovery was measured.  For one set of samples, they were prepared as 
normal; each sample had 150 µL of methanol containing internal standard (500 nM), 50 
µL of sample at the desired concentration, and 50 µL of plasma.  All samples were 
vortex, centrifuged at 14,000 rpm, and the supernatant was transferred to an amber 
HPLC vial.  For the second set, samples were prepared by only adding 180 µL of 
methanol containing internal standard (500 nM) and 60 µL of plasma followed by vortex 
and centrifugation.  After centrifugation, 200 µL was taken from this sample was added 
with 50 µL of analyte at the desired concentration in methanol.  The recovery was 
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calculated by comparing the peak area of the analyte between the two separate 
preparations.  Table 6 shows the recovery was acceptable since it was consistent and 
reproducible for each analyte for over a concentration range of 10-2500 ng/mL.    
Short Term Stability 
Bupropion and major metabolites short term stability at room temperature for 36 hours 
was analyzed using 2 concentrations (low at 10 ng/mL and high at 2500 ng/mL) (n=3/ 
each analyte/concentration).  The same samples were analyzed at 0, 8, 16, 24, and 36 
hours to see if the peak area concentrations were maintained over time. For the high 
concentrations, none of the analytes showed a significant decrease in peak area; 
bupropion stayed within 82% of the 0 hour peak area over 36 hours, hydroxybupropion 
stayed within 91-102% over 36 hours, threohydrobupropion stayed within 97-101% over 
36 hours, and erythrohydrobupropion stayed within 99-101% over 36 hours.  For the low 
concentrations; bupropion’s peak area started to decrease at 16 hours (64% of 0 hour 
peak area), however, the other 3 analytes were able to maintain stable peak areas over 
36 hours.  Hydroxybupropion’s peak area over 36 hours at low concentrations were 
within 93-101%, threohydrobupropion’s peak area at low concentrations were within 
85.5-102% over 36 hours, and erythrohydrobupropion’s peak area at low concentrations 
were 87-92% over 36 hours.  Therefore, for analyzing our clinical samples, no samples 
were allowed to be at room temperature for more than 8 hours due to degradation of 
bupropion at low concentrations.   
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Carryover 
The upper limit of quantification (ULOQ) for each analyte (5000 ng/mL) was ran (n=3) 
followed by a blank plasma sample.  The percent from the peak area of the blank 
sample to peak area of the ULOQ was calculated to ensure no carryover was occurring 
for any of the analytes(<20%).  This was also performed with the internal standard 
where the carryover needed to be less than 5%.   For our samples, the maximum 
carryover observed was <2% for each analyte and internal standard.    
Clinical Sample Analysis 
All clinical samples were stored at -80 ºC until sample analysis.  Each sample was 
prepared with 50 µL of plasma, 50 µL of methanol, and 150 µL of internal standard (500 
nM) in methanol.  All samples were vortex for one minute, centrifuged, and supernatant 
was analyzed by LC-MS/MS.  Runs were only considered acceptable if 67% of the QC 
samples were in the appropriate range (85-115% except the LLOQ acceptable range 
was 80-120%).   
Conclusion 
 We were able to successfully develop and validate a sensitive, accurate, 
reproducible method to detect bupropion and major metabolites in human plasma using 
LC-MS/MS.  We were able to use this method to detect bupropion and its major 
metabolites in our clinical trial to evaluate the concentration of bupropion and 
metabolites in plasma for the various formulations and doses.   
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Table 3-1.  MRM Parameters.  The transitions for each analyte are shown in this table 
as well as the MS optimization for collision energy, declustering potential, entrance 
potential, and collision cell exit potential.    
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Figure 3-1.  MRM Chromatograms of Blank Plasma Samples for Selectivity.  The 
left side of the chromatogram represents no detections of analytes.  The right side of the 
spectra represents no detections of internal standard.  Average of noise =50 CPS. Data 
represents (n=3).  
 
 
 
72 
 
 
Figure 3-2.  MRM Chromatograms of Blank Samples with IS for Selectivity.  The 
chromatograms represent the detections of internal standard at 500 nM and no 
interference of analyte detection. Average Retention Time: 11.2±0.12 minutes. Average 
Peak Height: 1.5X10^3 CPS. Data represents (n=3).  
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Figure 3-3. Specificity for Bupropion and Metabolites. One chromatogram for each 
analyte is shown; (A) bupropion (B) hydroxybupropion (C) threohydrobupropion (D) 
erythrohydrobupropion. The LLOQ was determined for each analyte.  We ensured that 
both the S/N was less than 3 and (E) peak area of each analyte was at least 5X greater 
than blank.   
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Analyte Linear 
Range 
(ng/mL) 
Linear Equation R^2 Lower Limit of 
Quantification 
(LLOQ) 
(ng/mL) 
Bupropion 2.5-5000 Y=0.00251x+0.00723 0.9941 2.5 
Hydrobupropion 5-5000 Y=0.00356x+0.0105 0.9904 5 
Threohydrobupropion 5-5000 Y=0.00985x+0.00572 0.9910 5 
Erythrohydrobupropion 5-5000 Y=0.00712X+0.0008 0.9902 5 
 
 
Table 3-2.  Standard Curves for Bupropion and Metabolites. Calibration curves for 
each analyte was ran for each batch of samples being analyzed.  The linear range and 
LLOQ seen in the table was consistent with each batch.  The coefficient of 
determination was 0.99 or greater for each batch.   
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Table 3-3.  Matrix Effect Analysis.  The matrix effect was determined by comparing 
the neat sample (in organic solvent) to a post-extraction spiked plasma sample.   The 
percentage of matrix effect (ME) was calculated by the peak area of post-extraction 
spiked sample divided by peak area of the neat sample (n=3).   The matrix has no effect 
on the samples.   
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Table 3-4.  Accuracy.  The accuracy of bupropion and major metabolites were 
analyzed both intra- and inter- day (n=5) over 3 days.  All analytes stayed with 85-115% 
of nominal concentration.   
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Table 3-5.  Precision.  The Precision for bupropion and major metabolite was monitor 
to ensure a %CV of 15 or less both intra and inter variability (n=5) over 3 days.  
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Table 3-6.  Recovery.  The recovery for bupropion and major metabolites were monitor 
to ensure reproducibility at low, medium, and high concentrations.  The peak area of the 
analyte post-spike to normal preparation.   
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Figure 3-4. Short term stability.  The short term stability was analyzed for each analyte 
by keeping samples at room temperature for 36 hours.  Plots represent any decrease in 
peak area stability over this range of time.  Bupropion was measured at (A) low and (B) 
high concentration, hydroxybupropion stability was measured at (C) low and (D) high 
concentration, threohydrobupropion was measured at (E) low and (F) high 
concentration, and erythrohydrobupropion was measured at (G) low and (H) high 
concentration.  Low concentrations were 10 ng/mL and high concentrations were 2500 
ng/mL.   
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Figure 3-5.  Carryover.  The ULOQ of each analyte was ran followed by blank sample.  
The percent from blank sample to ULOQ was calculated to determine if carryover 
existed. (A) bupropion; (B) hydroxybupropion; (C) threohydrobupropion; (D) 
erythrohydrobupropion. 
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  Chapter 4
Investigate Different Release Mechanisms that May Alter Absorption, Metabolism, 
and Pharmacogenomics of Bupropion.  
Abstract 
 The purpose of these studies was to evaluate whether different release 
mechanisms of bupropion changes absorption or metabolism of bupropion following 
immediate release, sustained release, and extended release formulations; and to 
estimate in vivo release and absorption rate of bupropion following modified release 
(MR) products.  We performed a 6 phase cross-over study with healthy individuals and 
collected plasma samples to quantify bupropion and the major metabolites after being 
dosed by one of the various formulations.  We observed that ER products showed a 
decrease in relative bioavailability compared to the reference IR products.  When we 
compared the AUC (m)/ AUC (p), there were no differences among formulations for 
each of the ratios for any of the metabolites.  Bupropion products showed high inter-
subject pharmacokinetic variability, which may be amplified by different release rates.  
Using Weibull type absorption, we were able to describe the absorption rate of 
bupropion’s MR products.  When we looked at the systemic appearance of drug among 
the different formulations, the absorption of bupropion was complete by 2 hours for the 
immediate release formulations, 4-6 hours for the sustained release formulations, and 
10 hours for the extended release formulations.     
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Introduction 
Bupropion HCl is a clinically available drug product that was first marketed as an 
immediate release (IR) product and was approved in the 1980’s; however, the IR 
formulation is dosed 3 times daily.  To help with patient compliance, a sustained release 
(SR) (b.i.d.) and extended release (ER) (q.d.) became available in 1996 and 2003 
respectively [1, 2].   
Bupropion is a CNS drug used for major depression, smoking cessation, and 
seasonal depression [6-9].  Bupropion is a BCS class I drug due to its high permeability 
and high solubility [10].  It is extensively metabolized to form 3 primary active 
metabolites; hydroxybupropion and the diastereoisomers threo/ erythrohydrobupropion 
by Cytochrome P450 2B6 (CYP2B6) and Carbonyl Reductase (CR) respectively [11-
14].  Using an animal model, it was shown that these metabolites might exhibit as much 
as 25-50% potency compared to bupropion [15, 16].  Bupropion is 87% excreted in 
urine (0.05% unchanged) and 10% eliminated in feces.     
To date, there is a gap in comparing these different formulations both in terms of 
efficacy and its pharmacokinetics [3].  Studies have suggested that these formulations 
are bioequivalent; however, bupropion has been noted for its high inter-patient 
variability and differences in plasma concentrations are normally observed [4, 5].  We 
proposed that if different release profiles caused changes in absorption, metabolism, 
and were differences in polymorphisms influencing this as well.  Therefore, we 
conducted a clinical trial consisting of a single dose, 6 phase, crossover study where all 
participants were randomized to one of the formulations at two different doses to 
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explore aspects relating to absorption and metabolism to see if this variability can be 
explained.    
Using the clinical data samples analyzed by LC-MS, we extensively looked at 
metabolism by comparing the concentration of bupropion and its major metabolites in 
plasma for each formulation as well as genotyping these participants for CYP2B6 to see 
if any variability can be related to polymorphisms in this metabolizing enzyme.  
Similarly, we examined absorption and the rate of absorption to look at differences 
amongst these formulations.  In typical pharmacokinetics, drug absorption rate is 
described by a first order process [17].  An alternative to this model is the flip-flop model 
which is typically observed with modified release products [18].  In this model the drug 
absorption is slower than elimination, therefore the terminal slope tends to show the 
absorption phase (ka) rather than elimination (Ke) [19].  Several papers have highlighted 
alternative methods for measuring absorptions.  One paper specifically highlights 
atypical absorption profiles aside from first order absorption; including parallel first order 
absorption, mixed zero-order and first-order absorption, Weibull-type absorption, 
absorption window with or without Michaelis-Menten, and time-dependent absorption 
[20]. For the purpose of these studies, we focused on Weibull-type absorption as it 
allows the absorption rate to change over time.   
In our study, we showed that metabolism did not contribute significantly to the 
variability observed in PK parameters.  Bupropion’s ER products showed lower relative 
bioavailability compared to the immediate release products.  Finally, we demonstrated 
that bupropion’s absorption rate can be described by Weibull-type absorption and 
absorption rate for all products were complete by 10 hours or less.  
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Materials/ Methods 
Clinical Trial/ Patient Recruitment 
This study was approved by both the Food & Drug Administration Institutional review 
board (IRB) and the University of Michigan IRB for both the protocol and informed 
content (HUM00081894).  All participants signed an informed content (IC) before drug 
was administered.   
Study Subjects, recruitment, screening, and contentment 
The data analysis performed here was with 14 participants who have completed the 
study (one participant dropped from the study after 2 phases).  There were no 
sex/gender or racial/ethnic group excluded from this study; although healthy participants 
had to meet the inclusion/ exclusion criteria (see below).  To date the demographics our 
study are outlined in Supplemental Table 1.   
Details Highlighting Inclusion and Exclusion from Protocol 
Inclusion Criteria Exclusion Criteria 
 Healthy volunteers 25 to 55 years old. 
 
 Subjects are willing to participate in the 
study as indicated by giving informed 
consent. 
 
 Volunteers have a BMI within a range 
of 18.5 to 35. 
 
 Willing to be medication and 
supplement free 2 weeks prior to 
beginning study, and throughout the 
study. All forms of birth control are 
okay. 
 
 Willing to abstain from alcohol for 
duration of study. 
 Patients unwilling or unable to comply with 
the study protocol 
 
 Patients unwilling or unable to take 
bupropion or have an allergy to bupropion 
 
 Any medical or surgical conditions which 
might significantly alter bupropion 
absorption and pharmacokinetics (e.g., 
history of malabsorption, liver cirrhosis) 
 
 Any medical or surgical conditions which 
might significantly interfere with the 
functions of gastrointestinal tract (e.g., 
gastric/intestinal bypass surgeries, irritable 
bowel disease, chronic narcotic use) 
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 Willing to adhere to all other protocol 
requirements as outlined in the 
informed consent document. 
 
 Not Pregnant 
 
 Individuals with a history of psychiatric or 
neurological illness, including seizure 
disorders 
 
 Individuals with a documented history of 
poor adherence to medical treatments and  
attendance to appointments for medical 
procedures or clinic visits  
 
 Any patient currently receiving known 
CYP2B6 inhibitors or inducers and 
unwilling to be medication free for two 
weeks. 
  
 Pregnant or nursing women 
 
 Administration of investigational drugs or 
any medication (prescription or over the 
counter or herbal) within the proceeding 2 
weeks of the study and throughout the 
study, with the exception of birth control. 
 
 Alcohol dependency. 
 
 Nicotine dependency. 
 
 
After prescreen, each subject vitals were obtained to assure participants were 
considered “healthy” according to our study.  This was defined as having normal vital 
ranges for lipid levels, blood glucose, blood urea nitrogen (BUN), creatinine, passed the 
urine drug screen, thyroid-stimulating hormone (TSH), complete blood count (CBC), 
electrolytes, and BMI with in a range of 18.5-35.  If subjects met these criteria, they 
were randomized to start phase I.  Each subject who entered the trial went through a 6 
phase cross-over study voluntarily with the 6 various phases (3 formulations; immediate 
release 75 & 100 mg, sustained release 100 & 150 mg, and extended release 150 & 
300 mg) of bupropion.  Before entering the next phase, each subject had a 10 day wash 
out period to ensure the drug was completely eliminated.  Before the drug was 
administrated, each subject fasted for at least 10 hours and had to refrain from water 
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one hour pre- and post- dosing.  When drug was administered the participant received 
240 mL of water.  Blood samples were obtained at the following hours; 0, 0.5, 1, 2, 3, 4, 
6, 8, 12 (for ER only), 24, 48, 72, and 96 hours.  During each phase, participants 
reported any adverse events they might have experienced; these were very few and 
were minor (Supplemental Figure 2).  After blood samples were taken, they were spun 
down (2000 g, 10 minutes, 4ºC) to extract plasma.  In addition to the pharmacokinetics 
samples, one whole blood sample was taken for genotyping purposes.   
Liquid chromatography/ Mass Spectrometry-Mass Spectrometry 
Samples were analyzed by LC-MS/MS; see chapter 3 for a detailed description of the 
method used for this as well as sample preparation.  Briefly, samples were stored at -80 
ºC until they were analyzed.  Samples were thawed on ice.  Samples were prepared 
with 50 µL of plasma, 50 µL of methanol, and 150 µL of IS (500 nM) in methanol.  
Calibrations curves (preparation described in chapter 3) were prepared fresh for each 
batch as well as fresh QC samples (2X low, medium, and high concentrations 
peranalyte).  All samples were vortex and centrifuged at 15,000 rpm.  The supernatant 
was analyzed by LC-MS/MS.    
Genotyping Methods 
Whole blood was used for DNA extraction using the salt precipitation method [21]. The 
CYP2B6 polymorphisms; rs8192709, rs3745274, rs45482602, rs2279343, rs3211371, 
and rs34223104 were chosen based on a literature review in which specific CYP2B6 
variants were associated with alterations in enzyme activity [14, 22, 23]. Polymorphism 
rs34223104 (T/C) is located 82 nucleotides upstream of the protein coding portion and 
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is associated with increased transcription of CYP2B6 but only has a minor allele 
frequency (MAF) of 0.012% (from the 1000 genomes project). Other CYP2B6 selected 
polymorphisms located on the extronic portion of the allele and allelic frequency varies 
in different populations [22]. Genotyping was completed by polymerase chain reaction 
followed by pyrosequencing [24]. 
Variant Alleles Description 
We selected five different CYP2B6 variant alleles to genotype (see table below). Due to 
linkage disequilibrium, certain polymorphisms are often inherited together to construct 
specific variant alleles [25]. The most common CYP2B6 variant allele observed in 
previous population studies is CYP2B6 *6, which is comprised of both the K262R and 
Q172H polymorphisms.  
CYP2B6 variant alleles.  
Reported activity changes are noted in the second column when known. 
Variant Associated SNP Suggested 
Phenotype 
Allele Frequency % (95% Cl) 
[37] 
CYP2B6*1 *1- Wild type (WT) 
allele, or the NCBI 
reference allele 
 54.5 (48-61) 
Cyp2B6*2 R22C  5.8 (3.3-9.7%) 
Cyp2B6*3 S259R  Found in a small 
number of Caucasian 
people 
0 (0-1.9%) 
Cyp2B6*4 K262R Increase metabolism 5.0 (2.7-8.7%) 
Cyp2B6*5 R487C Decrease Metabolizer 9.5 (6.2-15%) 
Cyp2B6*6 K262R + Q172H-  Occurs with the 
highest frequency 
among populations.  
Suggested that 
homozygous show 
25 (20-31%) 
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decrease in activity 
(but no transcription 
changes). 
Cyp2B6*7 Q172H, K262R, 
R487C- MUCH 
lower frequency 
than *5 or *6 
MUCH lower 
frequency than *5 or 
*6 
 
0 (0-1.9%) 
Cyp2B6*9 Q172H Frequency is very low 
in all populations. 
n.a. 
Cyp2B6*22 T-82C Increased expression n.a. 
 
Data Analysis 
Data analysis was performed in Phoenix WinNonlin (6.3) using noncompartment 
analysis to estimate the AUC, Cmax, and Tmax for each individual for each formulation.  
The Weibull function was used to model the absorption rate using non-linear mixed 
effect modeling software (NONMEM) version 7.3.0. with a subroutine of ADVAN 6 for 
estimate of alpha, beta, CL, and Vd.  The Weibull equation (1) was set to estimate Ka in 
NONMEM.  The differential equations constructed for the ADVAN 6 setting are shown 
below (2 & 3).  Equation 2 described the disappearance of the drug from the GI and 
equation 3 described the appearance of drug in the blood.   
𝐾𝑎 =
𝑏𝑒𝑡𝑎
𝑎𝑙𝑝ℎ𝑎
∗ (
𝑡
𝑎𝑙𝑝ℎ𝑎
)
(𝑏𝑒𝑡𝑎−1)
∗ 𝐸𝑋𝑃 (−
𝑡
𝑎𝑙𝑝ℎ𝑎
)
𝑏𝑒𝑡𝑎
 (1) 
𝑑𝐴
𝑑𝑇
=  −𝐾𝑎 ∗ 𝐴(1)                (2) 
𝑑𝐴
𝑑𝑇
= 𝐾𝑎 ∗ 𝐴(1) − 𝐾10 ∗ 𝐴(2)     (3) 
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The rest of the data analysis to examine the absorption and metabolism was performed 
in RStudio v0.99.464.   
Results 
The following analysis was performed with 14 completers who finished all 6 
phases for data analysis.  Each subject received a single dose of bupropion (IR 75 or 
100 mg, SR 100 or 150 mg, or ER 150 or 300 mg) during each phase.  All subjects 
were treated and monitored according to our protocol and informed consent; and any 
adverse events (AE) were reported to the IRB Committee. 
All PK blood samples were drawn and spun down to collect plasma for LC-
MS/MS analysis.  The LC-MS/MS method was validated according to the FDA 
bioanalytical method development and validation (see chapter 3).  Figure 1 shows the 
time vs plasma concentration based off the mean ± standard deviations for each 
formulation at various doses for bupropion and metabolites.  Table 1 summarizes the 
area under the curve (AUC) and the percent of coefficient of variation (%CV) associated 
with each formulation and each analyte.  There was a large inter-patient variability 
observed within each formulation.  
We conducted model based drug development analysis with our clinical data to 
compare the various formulations (IR, SR, and ER).  To begin, we examined how 
bioavailability might vary across different formations.  Using the relative bioavailability, 
we saw that with the ER formulations; there was a decrease in relative bioavailability 
compared to IR formulations for bupropion (figure 2).  For the 100 mg IR formulation, 
the relative bioavailability was 92% of IR 75 using the geometric mean.  For the SR 
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formations, a slight decrease in bioavailability was observed at higher doses, the 
geometric mean showed 78 & 110% for SR 150 & SR 100, respectively compared to IR 
75.  However, for the ER formulations geometric mean was 55-64% of the IR75.  
Likewise, when we looked at the arithmetic mean, we saw a decrease in relative 
bioavailability for the ER formulations (table 2), where the relative bioavailability was 
56-64% of the IR 75 AUC.  Again, this confirmed that for bupropion’s systemic 
appearance, the ER formulations had lower systemic exposure compared to the IR 
formulations.   
Since these metabolites are thought to exhibit as much as 25-50% potency 
compared to bupropion, we questioned whether the decrease in bioavailability for ER 
formulation might be compensated for by the increase in metabolite formation.  
Therefore, we went on to analyze the AUC (m)/AUC (p) to see if we saw a higher ratio 
for the ER formulation (figure 3).  However, due to the high inter-subject variability, we 
saw no statistical difference in AUC (m)/AUC (p) amongst the formulations for each 
metabolite.  This suggested to us that either regional GI metabolism or increase 
metabolism due to more exposure in GI tract was not accounting for this difference.   
Similarly, we looked at the pharmacogenomics to see if polymorphisms in 
CYP2B6 produced differences in hydroxybupropion which might be accounting for any 
of the variability.  In figure 4, we summarized the different variants of CYP2B6 
observed in our population.  Our population showed a pretty homogenous expression, 
without observing much variability in expressing different variants of CYP2B6.  In the far 
column we indicated the potential genotypes of these individuals.  As noted, most of our 
population is thought to be CYP2B6 *5/*6. 
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Next we went on to examine the absorption of the various formulations for 
bupropion HCl.  We applied Weibull type absorption to describe oral absorption (figure 
5).  Here it was shown the rate of absorption for the immediate release product was 
completed by 2 hours.  The SR products absorption was completed by 4-5 hours.  
Finally, it was shown that for ER products, absorption was completed by 10 hours.  This 
suggested that if any of the ER formulation was released after 10 hours, absorption was 
minimal or not occurring.  Finally, we looked at the accumulation of bupropion 
absorption (figure 6).  This demonstrated the amount vs time of bupropion percent 
absorbed in vivo.  This was normalized by the relative bioavailability (IR 75 as 
reference).   Altogether, Weibull type absorption was able to accurately describe oral 
absorption for bupropion and differentiate various release patterns.    
Discussion 
 We observed that bupropion ER products showed a decrease in bioavailability 
compared to IR products.  Increase metabolism for ER formulations or polymorphisms 
in CYP2B6 was unable to explain differences.  There was high variability that was 
observed in both bupropion and metabolite concentrations.  Finally, we showed using 
Weibull type absorption we were able to describe the various release of the different 
products and the absorption was near complete by 10 hours or less for all products.  
Bupropion is extensively metabolized to form 3 active metabolites.  The 
metabolite formation has been highly studied in vitro [13, 14, 26, 27].  Likewise, it has 
been shown that CYP2B6 is both highly variable in expression and activity which might 
cause as much as 20-250 fold inter-individual variation [28].  Likewise, it was shown that 
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hydroxybupropion formation can vary as much as 80 fold in vitro using liver microsomes 
[29].  Therefore, we thought that metabolism might be able to explain the variability that 
has been associated with bupropion products.  However, the AUC (m)/AUC (p) nor 
polymorphisms in CYP2B6 were able to significantly account for this difference.  
However, our population for genotyping CYP2B6 was small and might have showed 
more of an effect with more participants.       
Since bupropion HCl has never been dosed IV in human we don’t have an 
absolute bioavailability for bupropion.  Therefore, we used the relative bioavailability 
where all formulations/ doses were referenced to IR 75.  The IR formulations are less 
complex compared to MR formulation; they do not have the complication of a release 
rate/ mechanism before absorption.  Whereas, IR will only be govern by the 
disintegration, dissolution, and permeability for absorption since this a BCS class I drug 
[30].  
Typically pharmacokinetics explains oral absorption as first order process.  
However, for MR formulations there has been discrepancy whether first order or flip-flop 
absorption holds true [34].  In fact, it has been highlighted that flip-flop kinetics hold true 
to very few drugs and the typical drugs to follow this model are Class 3 or 4 in the 
biopharmaceutical drug disposition classification system, which bupropion is not [34].   
We examined atypical absorption that might occur using the Weibull type absorption. 
This has been highlighted as an appropriate method for measuring absorption rates for 
pharmacokinetics especially for absorption that might change overtime [20, 35, 36], as 
seen in MR formulations.  Here we showed using Weibull we were able to describe 
bupropion absorption rate and absorption amount in vivo.  We saw that no absorption 
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occurred after 10 hours. This becomes especially important for modified release 
formulations which are designed to release beyond 10 hours.  Although this phenomena 
works well with bupropion, further validation and research toward this idea would need 
to be explored.   
It has been highlighted that the average transit time for drug in stomach and 
small intestinal is on the order of 3.5 hours (0.25 hours in stomach and 199 minutes in 
small intestines) [31, 32]; although this can be highly variable and many factors 
influences this.  One prolonging factor is gastric emptying, which is influenced by many 
things including caloric intake, liquid vs solid intake, size of particles, enteric coated or 
sustain-release table, and more [17].  In this study, food should not have played an 
effect on gastric emptying because the participants were fasted; however, the modified 
release formulations may have had slower gastric emptying rates and thus longer time 
in the GI tract.  In fact, MR products are designed for this purpose.  However, we 
showed that the absorption for bupropion was attenuate at 10 hours.  One can 
hypothesize that at this time, the drug may be in large intestines at this point.  Drug 
absorption occurs at a higher extent in small intestines compared to the large intestines 
due the increase surface area from microvilla and villa [33].  Therefore, if the drug is in 
the large intestines less absorption may be occurring to cause a decrease in 
bioavailability.  Another hypothesis is that there is a problem with the drug release 
mechanism that may be causing the drug not to be release from the ER formulation.  
However, this would further need to be validated before we could draw a conclusion.       
In conclusion, these findings illustrate how complex MR products are.  Typically 
the IR formulation is dosed three times daily, the SR formulation dosed twice daily, and 
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the ER formulation dosed once a day.  However, after normalizing concentration, we 
demonstrated that these formulations were not equivalent to systemic exposure after a 
single dose.  This is important because this could ultimately affect the efficacy in vivo 
and cause complication when switching amongst formulations.  Whether there is 
accumulation that might occur with multiple dosing or steady state would further need to 
be validated.     
  
 
 
95 
 
References 
1. Fava, M., et al., 15 years of clinical experience with bupropion HCl: from 
bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin 
Psychiatry, 2005. 7(3): p. 106-13. 
2. Settle, E.C., Jr., Bupropion sustained release: side effect profile. J Clin 
Psychiatry, 1998. 59 Suppl 4: p. 32-6. 
3. Jefferson, J.W., J.F. Pradko, and K.T. Muir, Bupropion for major depressive 
disorder: Pharmacokinetic and formulation considerations. Clin Ther, 2005. 
27(11): p. 1685-95. 
4. Laizure, S.C., et al., Pharmacokinetics of bupropion and its major basic 
metabolites in normal subjects after a single dose. Clin Pharmacol Ther, 1985. 
38(5): p. 586-9. 
5. Preskorn. S., K.S., Bupropion Plasma Levels Intraindividual and Interindividual 
Variability. Annals of Clinical Psychiatry, 1989. 1(1): p. 59-61. 
6. Dwoskin, L.P., et al., Review of the pharmacology and clinical profile of 
bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev, 
2006. 12(3-4): p. 178-207. 
7. Foley, K.F., K.P. DeSanty, and R.E. Kast, Bupropion: pharmacology and 
therapeutic applications. Expert Rev Neurother, 2006. 6(9): p. 1249-65. 
8. Stahl, S.M., et al., A Review of the Neuropharmacology of Bupropion, a Dual 
Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin 
Psychiatry, 2004. 6(4): p. 159-166. 
9. Vassout, A., et al., Regulation of dopamine receptors by bupropion: comparison 
with antidepressants and CNS stimulants. J Recept Res, 1993. 13(1-4): p. 341-
54. 
10. Paudel. A., P.Y., Shrestha. S., Shrestha. S., Formulation and In-Vitro Evaluation 
of Controlled Release Tablet of Bupropion Hydrochloride by Direct Compression 
Technique and Stability Study. International Journal of Pharma Sciences and 
Research, 2014. 5(05): p. 186-192. 
11. Coles, R. and E.D. Kharasch, Stereoselective metabolism of bupropion by 
cytochrome P4502B6 (CYP2B6) and human liver microsomes. Pharm Res, 
2008. 25(6): p. 1405-11. 
12. Hesse, L.M., et al., CYP2B6 mediates the in vitro hydroxylation of bupropion: 
potential drug interactions with other antidepressants. Drug Metab Dispos, 2000. 
28(10): p. 1176-83. 
13. Molnari, J.C. and A.L. Myers, Carbonyl reduction of bupropion in human liver. 
Xenobiotica, 2012. 42(6): p. 550-61. 
14. Skarydova, L., et al., Deeper insight into the reducing biotransformation of 
bupropion in the human liver. Drug Metab Pharmacokinet, 2014. 29(2): p. 177-
84. 
15. Bondarev, M.L., et al., Behavioral and biochemical investigations of bupropion 
metabolites. Eur J Pharmacol, 2003. 474(1): p. 85-93. 
16. Damaj, M.I., et al., Enantioselective effects of hydroxy metabolites of bupropion 
on behavior and on function of monoamine transporters and nicotinic receptors. 
Mol Pharmacol, 2004. 66(3): p. 675-82. 
 
 
96 
 
17. Hirtz, J., The gastrointestinal absorption of drugs in man: a review of current 
concepts and methods of investigation. Br J Clin Pharmacol, 1985. 19 Suppl 2: 
p. 77S-83S. 
18. Yanez, J.A., et al., Flip-flop pharmacokinetics--delivering a reversal of 
disposition: challenges and opportunities during drug development. Ther Deliv, 
2011. 2(5): p. 643-72. 
19. Byron, P.R. and R.E. Notari, Critical analysis of "flip-flop" phenomenon in two-
compartment pharmacokinetic model. J Pharm Sci, 1976. 65(8): p. 1140-4. 
20. Zhou, H., Pharmacokinetic strategies in deciphering atypical drug absorption 
profiles. J Clin Pharmacol, 2003. 43(3): p. 211-27. 
21. Pistis, G., et al., Genome wide association analysis of a founder population 
identified TAF3 as a gene for MCHC in humans. PLoS One, 2013. 8(7): p. 
e69206. 
22. Kirchheiner, J., et al., Bupropion and 4-OH-bupropion pharmacokinetics in 
relation to genetic polymorphisms in CYP2B6. Pharmacogenetics, 2003. 13(10): 
p. 619-26. 
23. Zanger, U.M. and K. Klein, Pharmacogenetics of cytochrome P450 2B6 
(CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. 
Front Genet, 2013. 4: p. 24. 
24. King, C.R. and S. Marsh, Pyrosequencing of clinically relevant polymorphisms. 
Methods Mol Biol, 2013. 1015: p. 97-114. 
25. Charles, B.A., D. Shriner, and C.N. Rotimi, Accounting for linkage disequilibrium 
in association analysis of diverse populations. Genet Epidemiol, 2014. 38(3): p. 
265-73. 
26. Connarn, J.N., et al., Metabolism of bupropion by carbonyl reductases in liver 
and intestine. Drug Metab Dispos, 2015. 43(7): p. 1019-27. 
27. Meyer, A., et al., Formation of threohydrobupropion from bupropion is dependent 
on 11beta-hydroxysteroid dehydrogenase 1. Drug Metab Dispos, 2013. 41(9): p. 
1671-8. 
28. Wang, H. and L.M. Tompkins, CYP2B6: new insights into a historically 
overlooked cytochrome P450 isozyme. Curr Drug Metab, 2008. 9(7): p. 598-610. 
29. Faucette, S.R., et al., Validation of bupropion hydroxylation as a selective marker 
of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos, 2000. 
28(10): p. 1222-30. 
30. Martinez, M.N. and G.L. Amidon, A mechanistic approach to understanding the 
factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol, 
2002. 42(6): p. 620-43. 
31. Jamei, M., et al., Population-based mechanistic prediction of oral drug 
absorption. AAPS J, 2009. 11(2): p. 225-37. 
32. Yu. L.X., C.J.R., Amidon G.L., Compartmental transit and dispersion model 
analysis of small intestinal transit flow in humans. International Journal of 
Pharmaceutics, 1996. 140(1). 
33. Lin, J.H., M. Chiba, and T.A. Baillie, Is the role of the small intestine in first-pass 
metabolism overemphasized? Pharmacol Rev, 1999. 51(2): p. 135-58. 
 
 
97 
 
34. Garrison, K.L., S. Sahin, and L.Z. Benet, Few Drugs Display Flip-Flop 
Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of 
the BDDCS. J Pharm Sci, 2015. 
35. Heikkila, H.J., New models for pharmacokinetic data based on a generalized 
Weibull distribution. J Biopharm Stat, 1999. 9(1): p. 89-107. 
36. Piotrovskii, V.K., The use of Weibull distribution to describe the in vivo absorption 
kinetics. J Pharmacokinet Biopharm, 1987. 15(6): p. 681-6. 
37.      Kirchheiner J. et al.  Bupropion and 4-OH-bupropion pharmacokineticsin relation 
to genetic polymorphisms in CYP2B6.  Pharmacogenomics.  2003.  13 (10): p. 
619-26 
 
 
 
 
98 
 
 
Figure 4-1. Time vs Concentration Plots.  The following show the mean ± standard 
deviation for each formulations at the indicated dose (A) bupropion.  (B) 
hydroxybupropion. (C) threohydrobupropion. (D) erythrohydrobupropion. (n=14).  
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Figure 4-2.  Relative Bioavailability.  Each formulation was dosed normalized to look 
at the relative bioavailability using IR 75 as a reference.  The boxplot shows the 25-75% 
range.  The red dot represents the geometric mean and the black dot represents the 
median.   
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Figure 4-3.  Analysis of Metabolites.  The area under the curve for the metabolites/ 
area under the curve for parent (AUC(m)/AUC(p)) for each metabolite is shown (A) 
hydroxybupropion (B) threohydrobupropion (C) erythrohydrobupropion. 
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Figure 4-4.  Pharmacogenomics of CYP2B6.  We genotyped our clinical participants 
for CYP2B6.  Above summarizes the various single nucleotide polymorphisms (SNP) in 
our population.  We show both the amino acid substitution (AA sub) caused by the 
different SNP and the amino acid position.  Also, we show the SNP variant and where 
the loci are located on the genes.  RS# indicated the reference number in the literature.  
In the far column, each individual person’s possible variant is listed.   
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Figure 4-5.  Weibull Absorption Rate.  Using the mean concentration for each 
formulation, we described the absorption rate for each formulation using Weibull 
distribution 
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Figure 4-6. Cumulative Percent Absorbed.  The mean concentrations were used to 
calculate the percent absorbed in vivo vs time for each formulation.   
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Table 4-1.  Area Under the Curve. The table shows the AUC ± SD for each formulation 
and the %CV for each formulation for bupropion and metabolites (n=14).  
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Table 4-2.  Percent of Relative Bioavailability.  For each formulation the AUC for 
bupropion is shown using the arithmetic mean, the relative bioavailability was calculated 
using IR 75 as a reference.  
  
 
 
106 
 
 
Supplemental Figure 4-1.  Study Demographics.  Summarizes the demographic 
distribution of race, age, sex, and BMI of the participants who entered our study.    
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Supplemental Figure 4-2.  Adverse Events.  Above list any adverse events that 
occurred with our participants in the clinical trial.   
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  Chapter 5
Conclusions 
 
Summary of Findings and Significances 
Despite the fact that bupropion was approved clinically in the late 1980’s, there 
are still uncertainties about its pharmacology and metabolism [1, 2].  Many investigators 
still study in vitro metabolism of bupropion, even when the issues of bioineequivalence 
generic bupropion products surfaced in 2006 [3].  Although the drug product is 
prescribed to over 11 million people a year [4], it has been a challenge to figure out 
issues that still remain.  Although one would think that Bupropion PK should be simple 
since it has high permeability, high solubility, and exhibits linear pharmacokinetics at 
clinical dosing; it is in fact very complicated.  There are 3 formulations (immediate, 
sustained, and extended release) that are dosed up to 3 times daily, the drug is highly 
metabolized to form multiple metabolites in which the three primary metabolites are 
thought to be active [5, 6], and when studying this drug there is no in vitro dissolution/ 
IV/ or solution data for bupropion HCl.  Although these challenges remain, we try to 
unravel much about the metabolism of bupropion both in vitro and in vivo.   
Chapter 2 highlights many new finding for in vitro metabolism.  Specifically, it was 
thought that bupropion’s major metabolite was hydroxybupropion [7, 8].  However, many 
previous studies only used a microsomes system in which it is hard to capture the 
metabolites formed by carbonyl reductase.  A more appropriate system would be to use 
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an S9 fraction (which contains both microsome and cytosolic fraction) or even better yet 
hepatocytes.  When we used a hepatic S9 fraction, we saw that the formation kinetics 
for the metabolite threohydrobupropion was similar to the formation of hydoxybupropion.  
This is important clinically since it is thought that the major metabolites are active.  
Furthermore, we saw that threohydrobupropion was able to form in the intestines using 
an in vitro system.  This concept is important especially pertaining to a modified release 
product that might have more exposure in GI tract therefore forming more of this 
metabolite compare to an immediate release product.  
Initially when designing our clinical trial, we thought that that metabolism, 
specifically polymorphs in CYP2B6 could explain a lot of variability that is seen with 
bupropion’s plasma concentrations. In chapter 4, we investigated various formulations 
(immediate, sustained, extended release) of bupropion in healthy individuals to see how 
the pharmacokinetics might change (ie from GI regional metabolism).  In combination, 
we looked at genotyping these individual for CYP2B6.  Much to our surprise, CYP2B6 
could not account for much variability; in fact most of our population had similar 
expression of CYP2B6 variants.   
However, as discussed in chapter 4, we started to perform model based drug 
development analysis on the plasma concentrations for these various release products 
for bupropion.  Here we found that looking at the relative bioavailability (reference was 
IR 75), there was a decrease in bioavailability for the ER formulations and 150 mg SR 
formulation. Despite the heavy emphasis on designing these studies to focus on 
metabolism, we saw no difference in CYP2B6 polymorphs or AUC(m) / AUC(p) for any 
formulation or metabolites.   
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In addition in chapter 4, we highlighted bupropion’s absorption rate.  Specifically, 
modified release formulation which may not exhibit either typical first oral absorption or 
flip-flip kinetics, but rather can be outlined using atypical absorption [9].  Weibull type 
absorption has been purposed as one way to describe oral absorption [10-12].  By using 
Weibull we showed that absorption was attenuate after 10 hours.  This point becomes 
important with MR formulations that may be designed to release later than 10 hours.  In 
fact, this concept may be able to explain the decrease in bioavailability.  We 
hypothesize that the decrease in bioavailability for the MR products might not be 
releasing in the small intestines but instead the large.  Or, there may just be a release 
mechanism problem not allowing these formulations to completely release.  However, 
further investigations would be needed to confirm this.     
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  Appendix 1
Introduction to HSP70/ HSP90 
 
1. HSP90  
Heat shock protein 90 (HSP90) is a molecular chaperone involved in protein 
quality control.  In order to perform these functional tasks and maintain protein 
homeostasis, HSP90 cooperates with a network of co-chaperones, including 
tetratricopeptide repeat (TPR) domain-containing proteins (such as HSP70-HSP90 
organizing protein (HOP)).  HSP90 is involved in a number of cellular functions such as 
kinase, transcription, and steroid receptors which aids in the regulation of apoptosis, 
signal transduction, folding, maintenance, degradation, and cell-cycle regulation [1].  
 
HSP90 is conserved throughout most organisms.  Prokaryotes have one non-
essential form of HSP90 whereas Eukaryotes have several forms of HSP90 [2].  
Different isoforms of the HSP90 are produced by different genes.  To begin, two of the 
more common forms of HSP90 include the cytosolic forms.  The two isoforms of the 
cytosolic HSP90 are HSP90α and HSP9β which are encoded by the genes HSP90AA1 
and HSP90AB1, respectively [2].  HSP90α and HSP90β share 86% similarity in 
sequence, however, HSP90α is an inducible form whereas HSP90β is constitutively 
expressed [3].  In addition to the cytosolic form, an endoplasmic reticulum and 
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mitochondrial form exist; these forms are encoded by the genes HSP90B1 and TRAP1, 
respectively [4].  For the purpose of the studies presented here, we will focus on the 
cytosolic forms of HSP90 (both α and β).   
 
HSP90 exist as a dimer.  For each monomer, HSP90 contains an N-terminal 
domain that is 25 kDa.  Within the N-terminal of HSP90, the ATP binding pocket is 
located.  Following the N-terminal domain is a charged linker which connects the N-
terminal domain to the middle domain.  The middle domain (40 kDa) of HSP90 is where 
many substrates bind; the amphipathic loops in the structure of the middle domains 
allows for substrate binding.  Finally, the C-terminal of HSP90, which is about 12 kDa, 
contains an alternate ATP binding site.  The C-terminal is responsible for the 
dimerization of HSP90 [5].  More importantly, the C-terminal contains the MEEVD 
region.  This highly conserved region of HSP90 is important for many interactions with 
other proteins including the interactions with an important group of co-chaperones, 
tetratricopeptides domain (TPR) containing proteins [6].  The MEEVD nucleotide 
sequence within the C-terminal of HSP90 has been found to be an important binding 
motif for TPR containing proteins [7-9].   
 
HSP90 interacts with a variety of co-chaperones and client proteins to facilitate 
maturation.  During this process, HSP90’s structure goes through different 
conformational states. In the open state, the N-terminal lids of HSP90 are opened.  
Upon ATP binding to the N-terminal of HSP90, the lids close and the N-terminal domain 
rotates 120 degrees blocking the ATP binding site.  This causes a transient dimerization 
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of N-terminal to form a close state.  Finally, ATP hydrolysis occurs to return to the open 
confirmation state again [2].  In addition, co-chaperones assist HSP90 through these 
conformational states to form an early, intermediate, and mature chaperone complex.  
In the early complex, the co-chaperones Heat Shock Protein 70 (HSP70) and HSP70-
HSP90 Organizing Protein (HOP) are bound together and client proteins are capable to 
bind to HSP70.  In the intermediate complex, HSP90 comes into to the complex and 
binds with HSP70 with the help of HOP.  Client proteins can then be shuffled from 
HSP70 to HSP90 [10].    Upon an ATP hydrolysis, HSP70 leaves the complex and 
HSP90 finally forms the mature complex at which point HOP may or may not be replace 
with an alternative TPR containing protein.   Additionally, at this point, client proteins are 
folded into a state where they can perform their various functions or client proteins can 
be marked for ubiquitination and degraded by proteasomes with the help of the co-
chaperone, C-  terminus of Hsc70 interacting protein (CHIP) [11, 12].  
 
Although HSP90 is critical for normal cellular functions; dysregulation of HSP90 and 
dysfunction of protein homeostasis is linked to many diseases.  For example, HSP90 
plays a critical role in the folding and maturing of a number of oncogenic proteins in 
cancer cells [1].  Furthermore, the expression of HSP90 is increased in cancer cells [13-
17].  Currently, it is thought that increased levels of HSP90 sustain cancer growth by 
protecting oncogenic proteins from degradation, thereby preventing apoptosis [18, 19].  
Therefore, HSP90 has emerged as an ideal target in many disease states. 
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2. Targeting HSP90 
HSP90 is highly expressed in stressed cell; in normal cells HSP90 constitutes 1-2% 
of total cellular protein however, when cells become stressed, HSP90 raises to 4% of 
total cellular protein [20].  When these cells become stressed, HSP90’s expression 
increases and HSP90 matures mutated or oncogenic client proteins. This dysregulation 
of the complex has been associated with many disease states including cancer, 
neurodegenerative disease, metabolic disease, and more [21].  In fact, overexpression 
of HSPs is partially to blame for the reason resistance to current cancer therapy such as 
anti-tumor agents and chemotherapy occurs [22].  The exact reason for this is not 
known to date. 
 
The development of an HSP90 inhibitor has been an attractive area for many years.   
Specifically targeting HSP90 has been appealing due to the diversity of client proteins 
that become degraded by proteasomes when inhibiting HSP90.  Furthermore, studies 
have shown that inhibitors targeting HSP90 in cancerous cells have a 100 fold time 
greater affinity than normal cells containing HSP90 [23], meaning inhibitors would 
specifically target disease cells leading to reduce toxicity from off target effects.  One 
common attempt of targeting the HSP90 complex has been to inhibit the ATP binding 
site.  Geldanamycin and its derivatives, 17-AAG and 17-DMAG were one of the most 
promising candidates to target HSP90’s ATP binding site. These inhibitors made it to 
phase III of clinical trials, however due to the hepatotoxicity and poor solubility, the drug 
was not able to continue through clinical development [22].  Many similar approaches to 
inhibiting HSP90 have been attempted including targeting various protein-protein 
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interactions within this complex.  Despite many designs, challenges still arise at 
developing a successful HSP90 inhibitor that can make it through clinical trials.    
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3. Targeting HSP90 in breast cancer 
HSP90 is typically overexpressed in breast cancer.  Some common client proteins of 
HSP90 that are offend found to be mutated or oncogenic are p53, v-SRC, AKT, HER2, 
EGFR, estrogen/androgen receptor, and NF- κB [24, 25].  Breast cancer is a particularly 
appealing target since HER2 is one of the most sensitive client proteins [26].  The 
overexpression of both HSP70 and HSP90 has been associated with poor prognosis in 
cancer [27, 28]. Additionally, tissue microarrays showed that high expression of HSP90 
in breast cancer was associated with poor survival [29]. Therefore, it is thought that 
inhibiting HSP90 will lead in helping degrade a multitude of signaling pathways for 
breast cancer therapy as well as the high risk associated with HSP90 itself.     
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4. Heat Shock Protein 70 (HSP70) 
HSP70 is a weak ATPase chaperone protein that is also involved in protein 
quality control.  HSP70 is 70 kDa protein that exists as a monomer.  HSP70 has several 
functions including protein folding, degradation, transport, and aggregation prevention 
[30-36].    
In eukaryotes, there are several different HSP70 proteins.  Hsc70 is constitutively 
expressed and makes up 1-3% of total cellular protein whereas HSP72 is the inducible 
form of HSP70 that is highly expressed upon stress [37].   
HSP70 is regulated by two groups of proteins; one group of proteins, J- domain 
proteins which help to facilitate substrates binding to HSP70.  It is believed that HSP70 
exist in two conformational states that is dictated by ADP or ATP.  HSP70 is controlled 
by two domains; nucleotide-binding domain (NBD) and polypeptide substrate-binding 
domain (SBD).  The substrates affinity for binding to the SBD region is highly dependent 
on which state HSP70 is in.  HSP70’s N-terminal domain is 45 kDa.  Similarly to HSP90, 
there is an ATPase within the N-terminal of HSP70 which shuffles through ATP and 
ADP dependent states.  When ATP is bound, peptides are able to associate with SBD 
at high rates but low affinity.  After ATP hydrolysis by NBD, the affinity of substrates to 
SBD is high and the rate of association/dissociation is low [38-41].  Furthermore, 
another group of proteins, nucleotide exchange factors are also involved to determine 
the lifetime of the complex [42].  The C-terminal of HSP70 is 25 kDa [43].  The C-
terminal of HSP70 also accepts TPR containing proteins.  However, instead of the 
MEEVD nucleotide sequence seen in HSP90, HSP70 TPR motif contains an IEEVD 
nucleotide sequence motif.    
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5. Targeting HSP70 
Similar to HSP90, HSP70 has been correlated with various disease states.  
Targeting HSP70 has been an attractive target as well.  Like HSP90, there are also 
similar problems in developing a successful molecule to inhibit HSP70.  First, HSP70 
has been associated with diseases such as neurodegenerative disorders, cancer, and 
infectious disease [44-46].  HSP70 interacts with numerous signal transduction 
pathways, so inhibiting this protein would also aid in regulating a subset of other 
pathways.  Attempts at developing an inhibitor to HSP70 ATPase have been a hot area.  
Unlike the low affinity compounds towards HSP90s ATPase, compounds towards 
HSP70 have been on the mid-nanomolar scale [47].  However, the lack of functional 
effect has been seen with this approach [48].  It has been proposed that targeting 
protein-protein interactions within HSP70 might be a better option.  Specifically targeting 
HSP70 and TPR contain proteins, J proteins, or nucleotide exchange factors.  It was 
suggested that inhibiting different interaction may lead to different outcomes which 
might help maintain protein homeostasis [49].   
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6. Tetratricopeptides Repeat Domains Proteins 
The tetratricopeptide repeat (TPR) domain is a tandem repeat of 34 amino acid motif 
[50-52].  These proteins are highly conserve and many TPR containing proteins are 
involved in the HSP70 and HP90 complex such as; HOP, CHIP, PP5, CYP40, FKBP52, 
and FKBP51.  There are a variety of TPR containing protein functions including; 
isomerases, phosphatases, and ligases [52]; it is thought that HSP90 and HSP70 are 
universal acceptor of TPR domain proteins [3].  The binding site for TPR containing 
proteins is located in the C-terminal of HSP90 (MEEVD) and HSP70 (IEEVD) [7-9].  
TPR proteins can contain multiple TPR domains; such as HOP which has 3 TPR 
domain sites.  Typically the TPR domains are 3 sets of antiparallel alpha helices.  Within 
the TPR domain that contain a “carboxylate clamp” that consists of positive residues 
such as arginine’s and lysine’s that bind to the negatively charged residues, 
MEEVD/IEEVD, regions on HSP90/HSP70 [53].   
 
6.1 Protein Phosphatase 5 
Protein Phosphatase 5 (PP5) is one of a number of TPR containing proteins.  
PP5 is unique to the protein phosphatases family because it’s the only one to contain a 
TPR domain [54]. The TPR domain is located in the N-terminal of PP5.  The C-terminal 
of PP5 contains the catalytic site.  Within the catalytic domain lies a nuclear localizing 
signal.  PP5 was first discovered in the nucleus, it was later determined that it was also 
localized in the cytoplasm [55-57]. In addition, PP5 is an autoinhibitor protein; meaning 
that its typical expression is of basal level.  The alpha J helix located in the C-terminal of 
PP5 folds over to the N-terminal, where the HSP90 binding region is located.  In this 
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autoinhibitory state, catalytic activity does not occur.  It has been shown that HSP90 
and fatty acids, such as arachidonic acid can relieve this autoinhibition [58, 59].  At this 
point, when HSP90 binds to PP5, PP5 undergoes a conformational rearrangement 
which then allows substrates to bind and PP5 can perform phosphatase activity.  PP5 
has also been shown to have high affinity (on the nanomolar scale) for HSP90 [6, 59].  
PP5’s function in the HSP90 complex to date is still unclear; however, many studies 
show that PP5 does bind to HSP90’s MEEVD region [50, 52, 54, 60-62].  PP5 has also 
been shown to be involved in numerous signaling pathways, many which are also client 
proteins of HSP90 including MAPK, ASK, ATM, cyclinD, p53, steroid receptors, and 
more [63-68].  
 
Similar to HSP90, PP5 has also been implemented in cancer, particular breast 
cancer.  One study has suggested that PP5 causes cell growth in estrogen positive 
(ER+) breast cancer [69]. Similarly, another group showed using a xenograph model, 
overexpression of PP5 lead to a higher mean tumor diameter [70].  Additionally they 
showed that when they stained both invasive ductal carcinoma tumors and ductal 
carcinoma tumors, higher levels of PP5 were found in these tissues compared to normal 
tissues [70].  These evidences advocate PP5 as a good target in ER+ breast cancer.  
 
6.2 HSP70-HSP90 Organizing Protein (HOP) 
HOP, another TPR containing protein is known to bind not only HSP90 but also 
HSP70.  However, HOP differs from PP5 in that it has 3 TPR domains.  The first TPR 
domain, TPR1 is important for binding to HSP70.  The second TPR domain, TPR2A is 
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important for binding HSP90.  Finally the last TPR domain, TPR2B is undefined to date; 
however, some evidence show that it might be important to bind to HSP90’s N-terminal 
domain [71].  In addition, there are also two undefined domains of HOP referred to as 
DP repeat motif due to the aspartic acid (D) and proline (P) repeat motifs [72].  HOP 
resides in both the cytoplasm and nucleus.  The main function of HOP is to link HSP70 
and Hp90 together.  Many studies have indicated that the affinity of HOP for both 
HSP70 and HSP90 is on the high nanomolar/ lower micromolar scale depending on the 
platform of the assay [9, 73, 74].     
 
Likewise, HOP has also been implemented in disease states.  Particularly in cancer, 
it has been shown that increase expression of HOP lead to increase complex formation 
in human colon tumors [75].  In addition, it has been shown that when HOP was 
knockdown via RNAi, a decrease in invasive pancreatic cancer proliferation occurred.  
Furthermore, they also observed client proteins such as HER2, Bcr-Abl, c-MET, and v-
Src expression was reduced when HOP was knocked down [76].  Studies have also 
shown that compounds that were able to inhibit the HOP-HSP90 complex was able to 
decrease cancer cell viability in vitro [77].  This too, suggest targeting this TPR 
interaction for cancer therapy is ideal.   
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7. Specific Aims 
Our goal is to understand mechanisms as well as discovering and developing 
inhibitors to the chaperone complex.  First, we studied the mechanism of HSP70/90 
binding to the tetratricopeptide repeat (TPR) domain of protein phosphatase 5 (PP5).  
While it is known that HSPs can bind TPR containing proteins, less is known about the 
HSP70/90-PP5 interaction and their potential roles in protein homeostasis.  Therefore, 
we sought to characterize these protein-protein interactions through various biochemical 
assays.   
In addition, we performed a High Throughput Screen for inhibitors of HSP90-TPR 
containing proteins.  We hypothesized that compounds that block the TPR-HSP 
interaction will aid in a novel approach for breast cancer therapy.   
Aim 1: The Molecular Chaperone Hsp70 Activates Protein Phosphatase 5 (PP5) By 
Binding the Tetratricopeptide Repeat (TPR) Domain 
 
Aim 2: High Throughput Screen for Small Molecules to Block TPR containing Co-
chaperones-Hsp90 Chaperone Complex 
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(Adapted from Biamonte M.  Heat Shock Proteins 90 Inhibitors in Clinical Trials. J. Med. Chem. 2010, 53, 
3–17 3). 
Appendix Figure 1-1.  HSP90 Complex.  In a disease state, oncogenic proteins are 
matured for tumorigenesis.  However, if an inhibitor is present, client proteins will be 
marked for ubiquitination and degraded by proteasomes. 
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Co-Chaperone Contains 
TPR 
domain? 
Binding Site 
on HSP90 
Function 
HOP Yes C-Terminal HSP70-HSP90 organizing proteins which 
helps to link HSP70 and HSP90.  Moves 
back and forth from cytoplasm to nucleus 
[78]. 
PP5 Yes C-Terminal The exact function involved with the 
HSP90 complex unknown.  Evidence 
proposes that it might be important for 
dephosphorylation of kinase.  Also it’s 
been suggested that the HSP90-PP5 
interaction is important for regulating the 
steroid receptor [79].     
Cdc37 No N-Terminal Co-Chaperone that interacts with many 
kinases.  Helps stabilizes and promotes 
activity of the complex.  Important for 
signal transduction.  Cellular location is 
in the cytoplasm [80].   
CHIP Yes C-Terminal  E3 ubiquitin protein ligase which marks 
misfolded substrates to be degraded by 
proteasomes [81]. 
P23 No N-Terminal Participates in folding HSP90 and a 
number of cellular regulations.  Enters 
the mature complex and helps with the 
maturation of client proteins.  [82]  
Immunophillins 
(FKB51/52) 
Yes C-Terminal FKB51/52 are peptidylprolyl isomerase 
that associates with HSP90 to help 
intracellular trafficking of the steroid 
hormone receptor [83].   
 
 
Appendix Table 1-1.  Co-Chaperones that bind to HSP90. This summarizes important 
co-chaperones that bind to HSP90, functions of co-chaperones, and whether they 
contain TPR domains. 
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  Appendix 2
The Molecular Chaperone Hsp70 Activates Protein Phosphatase 5 (PP5) By 
Binding the Tetratricopeptide Repeat (TPR) Domain  
 
Abstract  
Protein phosphatase 5 (PP5) is auto-inhibited by intramolecular interactions with 
its tetratricopeptide repeat (TPR) domain. Hsp90 has been shown to bind PP5 to 
activate its phosphatase activity. However, the functional implications of binding Hsp70 
to PP5 are not yet clear. In this study, we find that both Hsp90 and Hsp70 bind to PP5 
using a luciferase fragment complementation assay. A fluorescence polarization assay 
shows that Hsp90 (MEEVD motif) binds to the TPR domain of PP5 almost 3-fold higher 
affinity than Hsp70 (IEEVD motif). However, Hsp70 binding to PP5 stimulates higher 
phosphatase activity of PP5 than the binding of Hsp90. We find that PP5 forms a stable 
1:1 complex with Hsp70, but the interaction appears asymmetric with Hsp90, with 1 PP5 
binding the dimer. Solution NMR studies reveal that Hsc70 and PP5 proteins are 
dynamically independent in complex, tethered by a disordered region that connects the 
Hsc70 core and the IEEVD-TPR contact area. This tethered binding is expected to allow 
PP5 to carry out multi-site dephosphorylation of Hsp70-bound clients with a range of 
sizes and shapes.  Together, these results demonstrate that Hsp70 recruits PP5 and 
activates its phosphatase activity which suggests dual roles for PP5 that might link 
chaperone systems with signaling pathways in cancer and development.  
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Introduction 
Protein phosphatase 5 (PP5) is a member of the PPP family of serine/threonine-
specific phosphatases and has been linked to signaling pathways that control growth 
arrest, apoptosis, and DNA damage repair [1-3]. Specifically, PP5 plays important roles 
in regulating the dynamic phosphorylation of p53, ASK-1, MAPK and many other 
signaling components [4-6]. PP5 also has been implicated in the regulation of 
glucocorticoid receptor, although the mechanism is controversial [1, 7]. Additionally, 
PP5 levels are elevated in human breast cancer [8]. Together, these studies have 
suggested that PP5 may be a novel target for anti-cancer therapies [9]. However, the 
catalytic subunit of PPP phosphatases is highly conserved and it has been difficult to 
develop selective, competitive inhibitors of these enzymes [10]. In addition to its 
catalytic domain, PP5 is the only member of the PPP family that contains an N-terminal 
tetratricopeptide repeat (TPR) domain [11, 12]. TPR domains are assembled from 
repeats of an amphipathic antiparallel-helix that assemble into superhelical structures 
bearing a concave central groove [13-16]. PP5 has been shown to interact with the 
molecular chaperones heat shock protein 70 (Hsp70) and heat shock protein 90 
(Hsp90) [17-21]. Specifically, PP5’s TPR domain binds to cytoplasmic Hsp90 homologs, 
Hsp90α (stress inducible) and Hsp90β (constitutively active), through a conserved 
MEEVD motif that is located at the end of the C-termini of these chaperones [17-20]. 
Although biochemical data illustrates that an MEEVD peptide has high affinity for PP5’s 
TPR domain (~50 nM), solution phase NMR studies revealed that this interaction is 
highly dynamic with only few enduring contacts [19, 20]. Comparatively less is known 
about how PP5 interacts with Hsp70. Co-immunoprecipitation studies suggest that PP5 
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binds Hsp70 [21], but it isn’t yet clear how PP5 interacts with this chaperone or whether 
the TPR domain is involved. Based on the Hsp90-PP5 complex, it is likely that this 
interaction occurs through the IEEVD motif at the C-termini of the cytoplasmic Hsp70 
family members, including heat shock cognate 70 (Hsc70; HSPA8) and heat shock 
protein 72 (Hsp72; HSPA1A). 
 
PP5 belongs to a family of TPR domain-containing co-chaperones that includes 
Hop (Hsp70/90 organizing protein), CHIP (carboxyl-terminus of Hsp70 interacting 
protein) and a number of immunophillins, such as FKBP52 (FK506 binding protein 
52kDa). Members of this co-chaperone family bind to Hsp70 and/or Hsp90 at these 
chaperones’ C-terminal EEVD motifs. In turn, the TPR co-chaperones are important 
regulators of chaperone function [16] [22, 23]. For example, complexes between CHIP 
and either Hsp70 or Hsp90 are linked to the ubiquitination and therefore the 
proteasomal degradation of chaperone-bound clients. Likewise, a complex between 
these chaperones and HOP is critical to the folding of some clients, such as nuclear 
hormone receptors [24-26]. Additionally, FKBP52 couples clients of Hsp70 and Hsp90 
to the cytoskeleton [27]. However, less is known about the Hsp70-PP5 and Hsp90-PP5 
complexes and their potential roles in the protein homeostasis network. One important 
clue comes from observations that the TPR domain and the C-terminal catalytic subunit 
of PP5 have an auto-inhibitory function, suppressing phosphatase activity. Indeed, 
binding of Hsp90 to the TPR domain has been reported to weakly activate PP5 [14]. 
However, it is not yet clear whether Hsp70 also binds the TPR domain or whether this 
interaction activates PP5. 
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Towards these questions, we characterized the interaction of Hsp70 and Hsp90 
with PP5, using a panel of cell-based assays and biophysical methods. These studies 
confirmed that PP5 binds Hsp70 and Hsp90 through the canonical EEVD motifs. 
However, we found that C-terminal peptides derived from Hsp90α/β bind to PP5 10-fold 
tighter than C-terminal peptides derived from Hsc70/Hsp72. Despite Hsp70’s weaker 
affinity for PP5, this chaperone was far more effective at stimulating PP5’s phosphatase 
activity. Additionally, solution phase NMR studies showed that Hsp70 and PP5 move 
independently of each other in the bound complex, suggesting that the disordered C-
terminus of Hsp70 allows the activated PP5 to “sample” a relatively large area around 
the chaperone. This ultra-structure might be important in allowing PP5 to act on a wide 
range of chaperone clients. Together, these results suggest that the Hsp70-PP5 
complex is a potent phosphatase that might link chaperone systems with signaling 
pathways in cancer and development.  
 
Material/ Methods 
Materials.  Reagents were obtained from the following sources: pLentilox vectors 
(University of Michigan Vector Core); pMSCG9 vector (Clay Brown, Center for 
Structural Biology, University of Michigan); restriction endonucleases (New England 
Biolabs, Ipswich, MA); HEK293 (American Type Culture Collection); Dulbecco’s 
modified Eagle media (Gibco Life Technologies, 11965-092); fetal bovine serum 
(10082-147); antibiotic-antimycotic (Gibco Life Technologies, 15240-062); 6-well tissue 
culture plate (BD Falcon, 3046); polybrene linker (Santa Cruz, sc-134220) Renilla GLO 
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Luciferase Kit (Promega, Madison, WI);  and pNPP phosphatase substrate kit  (Thermo 
Scientific, 37620).   
 
Plasmid Construction. C-terminal Renilla luciferase (CRL, residues 1-229) and full-
length Hsp70 or Hsp90 (upstream of CRL) were PCR-amplified and subcloned into a 
pLentilox RSV-2 dsRed vector using the following restriction site design: BamHI-Hsp72-
Xba1-CRL-Not1 and Xma1-HSP90α-BamHI-CRL-Xba1. In these fusion constructs, the 
stop codon of Hsp70/90 was deleted. Similarly, N-terminal Renilla luciferase (NRL, 
resides 230-311) and full-length PP5 (downstream of NRL) were amplified and 
subcloned into the pLentilox RSV vector using the following restriction site design: 
BamHI-NRL-Xba1-PP5-Not1. In this construct, the NRL stop codon was deleted. All 
fusion constructs (Hsp70/90-CRL and NRL-PP5) contained a GGGGSGGGGS (G4S)2 
peptide linker between the protein of interest and the Renilla luciferase reporter [28]. 
After all sequences were confirmed at University of Michigan DNA sequencing core, 
lentiviral particles containing these constructs were purchase (University of Michigan 
Vector Core) in order to create a stable cell lines for additional studies.   
 
Cell Transduction and SRL-PFAC Assay. HEK293 cells were plated using Dulbecco’s 
modified Eagle medium (DMEM) (Gibco Life Technologies) with 10% fetal bovine serum 
(FBS) and no antibiotics into a 6 well tissue culture plate.  Cells were allowed to adhere 
and grow for 1 day (~70% confluent) before transduction.  The next day, fresh media 
without antibiotics (1.35 mL), 0.15 mL of 10X lentiviral particle (either Hsp70-CRL, 
Hsp90-CRL, or NRL-PP5), and polybrene linker to a final concentration of 8 µg/mL was 
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added to each well.  After an incubation period of 8 hours at 37 °C and 5% CO2, the 
media was replaced with DMEM with 10% FBS and 1% antibiotic-antimycotic.  For cells 
that contained both HSP70/90-CRL and NRL-PP5 viral particles, the above procedure 
first performed with Hsp90/Hsp70-CRL viral particles.  Using these cells, the same 
procedure was repeated a second time; however, NRL-PP5 lentiviral particle was 
added.  The HSP70/90-CRL and PP5-NRL viral particles contained dsRED and GFP 
respectively.  Cells containing Hsp90-CRL, Hsp70-CRL, NRL-PP5, Hsp90-CRL + NRL-
PP5, and Hsp70-CRL + NRL-PP5 constructs were then seeded into a 24 well plate at a 
density of 5,000 cell/wells and allowed to grow overnight at 37 °C and 5% CO2.  The 
following day, the media was removed and the cells were washed with phosphate-
buffered saline. Luciferase activity determined using the Renilla-GLO Luciferase Assay 
System kit. Briefly, following washing, 100 µL of 1X passive lysis buffer was added to 
each well and plates were allowed to shake for 15 minutes at room temperature.  
Afterwards, 1X luciferase substrate was added and the luminescence was measured 
using Biotek Synergy 2 plate reader.   
 
Protein Purification. Full length PP5 and Hsp90 were expressed in Escherichia coli 
BL21 (DE3) cells from pMCSG9 plasmids. A fresh colony was grown in terrific broth 
(TB) medium supplemented with 50 mg/L ampicillin at 37 °C with shaking at 250 rpm 
until OD600 reached ~0.8 and protein expression was induced by the addition of IPTG 
(final concentration of 1 mM). The temperature was reduced to 18 °C and the culture 
was allowed to shake overnight. Cells were harvested by centrifugation (4000 x g, 10 
min, 4 °C). Cell pellets was suspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 
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10 mM Imidazole (pH=8.0)) and sonicated on ice, and clarified by centrifugation at 
15,000 x g for 30 min. The His-tagged proteins were purified using a Ni-NTA (Qiagen) 
column. The eluted protein was subjected to dialysis (PP5 buffer 40 mM Tris-HCL pH 
7.4, 10% glycerol, 1mM DTT and HSP90 buffer 20 mM Tris-HCL pH 7.4, 20 mM NaCl, 
10% glycerol, 1mM DTT). Proteins were treated with His-tagged tobacco etch virus 
protease TEV protease (1 µM) overnight at 4 °C to remove tags. This process was 
repeated a second time prior to extensive dialysis and removal of any residual His-
tagged protein by Ni-NTA column. Human Hsp70s (pMCSG7 vector) were expressed in 
E. coli BL21 (DE3) cells using TB medium supplemented with 50 mg/L ampicillin at 37 
°C with shaking at 250 rpm until OD600 of ~0.8 was reached. Additionally, Hsc70 protein 
was isotopically labeled for all NMR experiment. For labeled Hsc70, the BL21 cells were 
grown M9 media with15NH4Cl (Sigma Aldrich). The temperature was reduced to 18 °C 
and the culture was allowed shake overnight. Cells were harvested by centrifugation 
(4000 x g, 10 min, 4 °C). All Hsp70s were purified as described [29] and His tags 
removed via TEV protease. Final purification was performed on an ATP agarose 
column. All protein concentrations were measure using the Pierce BCA protein assay kit 
according to the manufacturer’s protocol.  To verify Hsc70 was not aggregated, the raw 
fluorescence values of the parallel and perpendicular intensity using fluorescence 
polarization shows no indication of aggregation. In addition, non-binding and binding 
tracer in fluorescence polarization was also used to confirm Hsc70 was not aggregated. 
NMR structure showed no sign of Hsc70 aggregation.  
Peptide Synthesis. All peptides were synthesized manually or with an ABI 433 peptide 
synthesizer using Fmoc chemistry with 2-Chlorotrityl resin as the solid support. Either 
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DIC/HOAt or HOBt/HBTU was used as the coupling reagent. Following completion of 
the peptide, a cleavage cocktail composed of TFA:TIS:H2O (19 mL: 0.5 mL: 0.5 mL) 
removed the peptide from the resin as well as any side-chain protecting groups. The 
resulting solution was evaporated and the crude peptide was precipitated with diethyl 
ether. Peptides were purified via RP-HPLC (Waters, Sunfire Prep C18, 19 mm x 150 
mm, 5 µm) and confirmed by electrospray ionization mass spectroscopy (ESI-MS) [30]. 
 
Fluorescence Polarization Assay. All fluorescence polarization experiments were 
conducted in 384-well, black, low volume, round-bottom plates (Corning) using a 
BioTeck Synergy 2 plate reader (Winooski, VT).  For binding experiments, to each well, 
was added increasing amounts of protein and the 5-carboxyfluorescein (5-Fam) labeled 
Hsp70/90 C-terminal probe/tracer (20 nM).  For competition studies each well had PP5 
protein at a concentration equivalent to the Kd, 5-FAM labeled peptide was held 
constant at 20 nM, and varying concentration of unlabeled peptide was added to 
compete off labeled peptide.  All wells had a final volume of 20 uL in the assay buffer 
(40 mM Tris-HCl, pH=7.4, 10% glycerol, 1mM DTT). The plate was allowed to incubate 
at room temperature for 5 min to reach equilibrium.  The polarization values in 
millipolarization units (mP) were measured at an excitation wavelength at 485 nm and 
an emission wavelength at 528 nm. An equilibrium binding isotherm was constructed by 
plotting the FP reading as a function of the protein concentration at a fixed 
concentration of tracer (20 nM). All experimental data were analyzed using Prism 5.0 
software (Graphpad Software, San Diego, CA) and WinNonlin (version 5.3)).  
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Protein NMR Experiments.  NMR data was collected using an Agilent/Varian NMR 
System with a room temperature triple resonance probe, interfaced to an Oxford 
instruments 18.7 T magnet (1H 800 MHz). Backbone assignments for the C-terminus of 
Hsc70 were previously reported [38]. Experiments for studying the interaction of PP5 
with Hsc70 were carried out using full-length PP5 and full length  15N labeled Hsc70 in 
the following buffer: 50 mM HEPES, 75 mM NaCl, 1 mM ADP, 5 mM MgCl2, 0.02% 
NaN3, 0.01% Triton pH 7.4, 30°C. The TROSY spectrum with 1:0 Hsc70:PP5 was 
recorded in 10 hours with a sample of 254 uM Hsc70. The spectrum with 1:1 
Hsc70:PP5 was recorded in 22 hours with a sample of 169 uM Hsc70 and 149 uM PP5.  
The two spectra have the same intrinsic signal to noise ratio ((254/169)2 = 2.25). 
 
Size exclusion chromatography and multi-angle light scattering (SEC-MALS): 
PP5:Hsp70 and PP5:Hsp90 complexes were formed by incubating proteins at equal 
molar concentrations (10 μM) in binding buffer (100mM KCl, 20mM HEPES [pH 7.5], 
7mM β-mercaptoethanol) at room temperature for 30 min.  Identification and molecular 
weight determination of complexes was achieved through SEC (Wyatt WTC-050S5 and 
WTC-030S5 columns) with an Akta micro FPLC (GE Healthcare) and in-line DAWN 
HELEOS MALS and Optilab rEX differential refractive index detectors (Wyatt 
Technology Corporation). SEC was performed in 100mM KCl, 20mM HEPES [pH 7.5]. 
Data was analyzed by the ASTRA 6 software package (Wyatt Technology 
Corporation).The two spectra have the same intrinsic signal to noise ratio 
((254/169)2=2.25) 
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p-Nitrophenyl Phosphate Assay.  Purified PP5, Hsp70, and Hsp90 were immobilized 
in 4HBX 96 well plates (thermo-scientific) and diluted with ELISA buffer (BioLegend).  
Equal molar concentration of protein was added to each well and incubation overnight 
at 4 degrees.  Protein concentrations ranged from 50 uM to 0.5 uM.  The following day 
p-Nitrophenyl Phosphate (pNPP) (Fisher Scientific) was used according to the 
manufactures protocol.  Once pNPP substrates were added to the plates, they were 
incubated at 37 degrees for 1 hour.  After color change, the OD405 was measured on 
the Biomatrix Plate Reader Synergy 2.  The enzymatic activity was calculated using the 
following equation. 
 
𝐸𝑛𝑧𝑦𝑚𝑒 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 
𝜇𝑚𝑜𝑙
min
𝜇𝑔
=
𝑉𝑜𝑙𝑢𝑚𝑒 ∗
𝑂𝐷405
𝑝𝑎𝑡ℎ𝑙𝑒𝑛𝑔𝑡ℎ
𝜀 ∗ 𝑒𝑛𝑧𝑦𝑚𝑒 ∗ 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛
 
 
Where ε is the molar extinction coefficient which equals 1.78*10^4 M-1*cm-1.   
 
Results 
SRL-PFAC confirms that Hsp70 and Hsp90 bind to PP5 in cells. 
Previous co-immunoprecipitation studies have suggested that PP5 interacts with 
both Hsp70 and Hsp90 in cells [21]. To confirm this result, we utilized the SRL-PFAC 
system, which has proven to be a powerful method for studying protein-protein 
interactions in cells [31]. In this assay, the full-length Renilla luciferase gene is divided 
into inactive halves, the N-terminal Renilla luciferase (NRL, residues 1-229) and the C-
terminal Renilla luciferase (CRL, residues 230-311). The NRL and CRL will reconstitute 
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functional luciferase if they are brought into close proximity. To explore whether Hsp90 
and Hsp70 bind PP5, we created constructs that would express NRL-PP5, Hsp70-CRL 
or Hsp90-CRL fusion proteins (Figure 1A). We anticipated that a luminescence signal 
would be detected only if Hsp90 or Hsp70 interacts with PP5 (Figure 1B). When 
HEK293 cells were transduced with viral vectors expressing either NRL-PP5, Hsp70-
CRL or Hsp90-CRL alone, low luciferase activity was measured (Figure 1C). However, 
co-transduction with either the NRL-PP5 + Hsp70-CRL pair or the NRL-PP5 + Hsp90-
CRL pair led to enhanced luciferase activity (Figure 1C), consistent with the interaction 
of PP5 with both chaperones in cells.  We also examined at a control pair (NRL-PP5 + 
HOP-CRL) if nonspecific complementation would occur. As expected no 
complementation of two luciferase fragments (NRL and CRL with low luciferase activity) 
was observed (data not shown).  
 
PP5 binds to the C-terminus of Hsp90 with higher affinity than to Hsp70. 
Binding of TPR co-chaperones, such as HOP or CHIP, to Hsp70 and Hsp90 is 
typically mediated by contacts between the TPR domain and the C-terminal EEVD motif 
that is shared by both chaperones [32-34]. To explore the affinity of the Hsp90 C-
terminus for PP5, we developed a fluorescent MEEVD tracer and measured its binding 
to PP5 by fluorescence polarization (FP). In this platform, the MEEVD tracer had a Kd 
value of 0.14 ±0.005 μM (Figure 2B), consistent with literature values [20]. This 
interaction appeared to be specific, because the reverse tracer (DVEEM) had weak 
affinity for PP5 (Kd > 10 μM) (Figure 2A). Next, we assessed the ability of an Hsp70-
derived IEEVD tracer to bind PP5. This tracer had a ~3-fold weaker affinity for PP5 (Kd 
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= 0.426 ± 0.06 μM) (Figure 2B). We were then curious to see if the homologs of the 
chaperones might have different affinities for PP5. We found that 10mer tracers derived 
from the C-termini of Hsc70 and Hsp72 had comparable affinities for PP5, with Kd 
values of 1.06 ± 0.34 and 1.55 ± 0.43 μM, respectively (Figure 2C). Additionally, the 
Hsp90α and Hsp90β tracers bound to PP5 with similar affinities, with Kd values of 0.079 
± 0.02 and 0.077 ± 0.02 μM, respectively (Figure 2C). The longer 10mer tracers also 
had affinities that were similar to those of their corresponding 5mers, suggesting that 
most of the affinity of the interaction is engendered by the EEVD motif. 
 
The results of the FP experiments suggested that the methionine of the MEEVD 
motif in Hsp90α/β may increase affinity for PP5. To test this hypothesis in more detail, 
we constructed tracers in which this position was mutated. Specifically, the methionine 
of the Hsp90α tracer was mutated to an isoleucine and the corresponding isoleucine of 
the Hsp72 tracer was mutated to methionine. As expected, the Hsp72 mutant tracer had 
higher affinity than the Hsp90α mutant tracer (0.133 ± 0.03 and 0.42 ± 0.02 μM) (Figure 
2D). These results clearly showed that the methionine contributed to the greater affinity 
of Hsp90-derived peptides for PP5.  
 
To further confirm these binding studies, we performed competition studies to 
compete unlabeled peptide with labeled peptide.  The IC50 values for the isoforms of 
HSP90 again showed higher affinity than HSP70 peptides in all 4 tracer competition 
assays (Figure 3A-D). For these experiments PP5 protein was added at a molar 
concentration that was equal to the binding affinity (Kd).  Therefore, for the competition 
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assay Hsc70 and Hsp72 contained more PP5 protein compared to Hsp90 α and β due 
to the lower affinity which can explain the similar IC50 among all four tracer assays.  
However, these results confirmed the binding experiments were correctly portraying the 
correct affinity.   
 
PP5 binds Hsp70 and Hsp90 in different arrangements. 
To better understand how the chaperones bind PP5, we incubated full length 
Hsp70 or Hsp90 with PP5 and analyzed the complexes by size-exclusion 
chromatography combined with multi-angle light scattering (SEC-MALS) to obtain an 
accurate measure of the molecular weight and stoichiometry of the complexes[35]. 
Additionally, both Hsp70 and Hsp90 are ATPase and they undergo dramatic 
conformational changes in response to nucleotides [36, 37]. When equimolar PP5 and 
Hsp70 are incubated and analyzed by SEC-MALS, a single peak predominates and is 
shifted in elution volume compared to individual runs of Hsp70 and PP5 (Figure 4A), 
indicating the formation of an Hsp70:PP5 complex. The average molecular weight of 
this peak was determined to be 145 kDa, and based on comparison with 126 kDa 
molecular weight calculated from the sequence, this corresponds to a 1:1 complex of 
Hsp70:PP5. When the Hsp90 dimer and PP5 are incubated together a single, shifted 
peak is observed as well, with a modest increase in molecular weight, 232 kDa 
compared to 190 kDa for Hsp90 alone (Figure 4B). This corresponds to an average of 
less than 1 PP5 bound per Hsp90 dimer indicating the formation of an asymmetric 
complex of Hp90:PP5 with a 2:1 stoichiometry despite the presence of two MEEVD 
binding sites in the Hsp90 dimer. Hsp90:PP5 interaction is likely weaker in affinity, 
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resulting in a partial dissociation during the elution, explaining the lower average 
molecular weight. The presence of saturating amounts of ATP and ADP were tested but 
resulted in no changes the molecular weight of the Hsp90:PP5 complex. Differences in 
the average molecular weight measured by SEC-MALS compared to the protein 
sequence were likely due to minor presence of aggregated PP5 and Hsp90 tetramer 
species (data not shown). Overall these results demonstrate that PP5 binds full-length 
Hsp70 and Hsp90 in vitro in different arrangements. Hsp70:PP5 is in a stable 1:1 
complex, while Hsp90:PP5 is in a 2:1 arrangement and may be slightly weaker in affinity 
compared to Hsp70.  
 
Hsc70 and PP5 move independently within the complex. 
 To explore the Hsp70-PP5 complex in greater detail, we utilized solution-state 
NMR. A 1H-15N TROSY HSQC spectrum was collected for 15N-labeled Hsc70 (1-646) in 
the ADP-bound state (Figure 5A in blue). As identified in our previous study where we 
investigated the interaction of Hsc70 with the highly homologous TPR protein CHIP [38], 
the middle of the TROSY spectrum (~7.5 to 8.5 ppm) is dominated by intense sharp 
resonances with a signal-to-noise ratio (SNR) of ~250:1 (Figure 5A).  These resonance 
were assigned using triple resonance experiments to residues 612-646 in C-terminal tail 
of Hsc70 as well as to a N terminal extension containing a tag [38]. The strong intensity 
of these resonances, as well as the lack of spectral dispersion, indicated that Hsc70’s 
C-terminal region (612-646), including the IEEVD motif, is a dynamically disordered 
random coil.  Based on comparison with published spectra of the isolated nucleotide-
binding domain (NBD) and the substrate-binding domain (SBD), the much weaker 
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signals with SNR ~ 8:1 in the well-dispersed part of the NMR spectrum in Figure 5 
originate from the 45 kDa Hsc70 NBD and 25 kDa SBD [38].  In the ADP state, these 
domains are tethered by a ~10 residue linker and move relatively independently [39-41].  
The large difference in peak intensity between the core region and the C-terminus is 
due to the large difference in TROSY transfer efficiency in molecules with an effective 
molecular weight of 25 - 45 kDa and a flexible tail with a much smaller effective 
molecular weight (which one estimates to be ~ 10 kDa on the basis of this intensity 
difference, see Table 2 and its legend). Increasing the contour level of the spectra 
focuses on the dynamically disordered region, which included the IEEVD motif (Figure 
5B). 
 
 The 1H-15N TROSY HSQC spectrum of 15N-labeled Hsc70 with PP5 in a ~1:1 ratio, 
shown in red in Figure 5 has the same intrinsic SNR as the spectrum of uncomplexed 
Hsc70 (see materials and methods).  With a KD of Hsc70-PP5 binding of ~ 1 uM (see 
above), 85% of the 169 uM Hsc70 should be complexed by the 149 uM PP5. 
Significantly, most of the Hsc70 resonances in the presence of PP5 did not change from 
those of Hsc70 alone (comparing red and blue overlay, respectively; Figure 5A). This 
result is unexpected. If the 60 kDa PP5 were to form a rigid 85 kDa complex with the 25 
kDa SBD, the SBD TROSY resonance intensities in the complex should drop 180-fold 
and become invisible; if it were to form a 105 kDa complex with the 45 kDa NBD, the 
NBD TROSY resonance intensities should drop 160-fold and become invisible; if it were 
to form a 130 kDa triple complex with SBD and NBD, the latter resonance intensities 
would drop 7000 and 1500 times, respectively (see Table 2 and its legend for these 
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calculations). In other words, if Hsc70 and PP5 were to form a rigid complex with either 
SBD or NBD core area’s TROSY-HSQC NMR spectrum would become undetectable at 
the conditions used.  In these scenarios, the NMR spectrum of the 15% uncomplexed 
Hsc70 would also drop below the SNR limit.  Hence, as we observe a largely 
unperturbed NMR spectrum for the Hsc70 core in the complex, we must conclude that 
the NMR data shows that the core regions of Hsc70 do not form stable complexes with 
PP5. 
 
 The NMR data do show that PP5 interacts with Hsc70’s C-terminus.  Several 
resonances in the high-level contour plot (Fig 5b) disappeared and/or shifted in the 1:1 
complex with PP5 (red spectrum). In particular, the intense resonances of the IEEVD 
motif residues disappeared completely from the NMR spectrum (Figures 5B and 5C), 
without new resonances appearing (also not at lower contour levels). This result is 
consistent with the dynamic C-terminus of an effective molecular weight of 10 kDa being 
immobilized by the 58 kDa PP5 protein forming a ~ 70 kDa complex. Table 2 shows that 
such a change in effective molecular weight results in a 430-fold reduction in TROSY 
peak intensity, which renders even peaks with an initial SNR of ~ 250:1 invisible.  We do 
not observe resonances for the ~ 15% free Hsc70, which should have an intrinsic ~ 40:1 
SNR.  It is most likely that the protein concentration estimation is not accurate and that 
there is no free Hsc70 in the sample. 
 
 Very significantly, the NMR spectra also show that the remaining peaks of the C-
terminal region (residues 610-640) do not disappear. This strongly suggests that this 
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area, located between the SBD of Hsc70 and the IEEVD motif, remains a dynamic 
random coil in the Hsc70-PP5 complex. Thus, the two proteins, while tightly bound 
through the IEEVD-TPR interaction, appear to move as dynamic, independent units 
tethered via Hsc70 residues 610-640.  
 
Hsp70 stimulates PP5’s phosphatase activity. 
In order to further understand the functional consequence of the Hsp70-PP5 
interaction, we utilized an in vitro phosphatase assay. Previous work illustrates that PP5 
maintains a basal level of phosphatase activity, which can be weakly stimulated by 
Hsp90 [14]. Thus, we assessed the ability of PP5 to hydrolyze the model substrate, p-
nitrophenyl phosphate (pNPP) in the presence of Hsp70 or Hsp90.  Importantly, neither 
Hsp70 nor Hsp90 interfered with the assay (Figure 6B), allowing us to determine their 
effects on PP5. Moreover, PP5 basal activity was very weak (Figure 6A), consistent with 
previous reports [42]. Interestingly, Hsp70 stimulated PP5’s phosphatase activity and 
this stimulatory activity was much greater than that of Hsp90 (Figure 6A). In addition, we 
also tested if 10mer C-terminal peptides (Hsp90α, Hsp90β, Hsc70, and Hsp72) would 
also stimulate PP5 activity. The data showed very little stimulation of PP5 activity when 
peptides were used (data not shown).  These results suggest that full length of Hsp70 
may play a significant role in activating PP5’s enzymatic activity.  
Discussion 
The chaperone activities of Hsp90 and Hsp70 are guided by interactions with co-
chaperones, including members of the TPR domain family. In turn, Hsp90 and Hsp70 
are thought to direct the activity of these co-chaperones towards specific clients. Our 
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studies confirmed that PP5 is a bona fide member of the TPR co-chaperone family and 
that it binds to both Hsp90 and Hsp70 through its TPR domain. Further, we found that 
Hsp90α and Hsp90β bind 10-fold tighter than Hsp70 family members. It isn’t yet clear 
whether this difference in affinity has physiological importance.  However, our study 
suggests that methionine plays important role in the affinity. Binding studies showed 
that most of the affinity of the Hsp70-PP5 and Hsp90-PP5 interactions is engendered by 
polar contacts with the EEVD motif and NMR studies confirmed that there are no 
significant stable interactions between other regions of the two proteins.  
 
The independent motion (tethered binding) of Hsp70 and PP5 in the solution 
complex suggests that the folded regions of these proteins are able to sample a 
relatively wide area. In the fully extended form, the disordered C-terminus of Hsp70 
could be expected to extend nearly 40 Å. We speculate that this flexibility and length 
might be important in allowing PP5 to find phosphorylated residues in bound Hsp70 
clients. Hsp70 clients are thought to include a number of kinases and transcription 
factors involved in apoptotic signaling. These clients have a wide range of sizes and 
shapes, so the flexibility of the tethered Hsp70-PP5 complex might be important in 
bringing activated PP5 in the vicinity of phosphorylated residues on these diverse 
targets.  
 
Exclusive, tethered binding to the Hsc70 EEVD terminus was recently observed 
for CHIP, an E3 ubiquitin ligase containing a TPR domain highly homologous to that of 
PP5 [38]. CHIP mediates broad-spectrum ubiquitination of Hsc70 client proteins 
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destined for the proteasome. For CHIP, tethered binding was thought to be important to 
allow the ligase to ubiquitinate diverse Hsp70 clients. Similar mechanisms might also be 
important in the Hsp90-PP5 complex, because Hsp90 also has a disordered region 
between its MEEVD motif and the folded portion of its C-terminus. 
 
We found that Hsp70 was a potent stimulator of the phosphatase activity of PP5. 
It is likely that binding of the IEEVD motif to the TPR disrupts the auto-inhibitory activity 
of the TPR domain, as has been observed in the Hsp90-PP5 system [14]. This agrees 
with our observation that PP5 forms a stable 1:1 interaction with Hsp70. Based on our 
purification methods we expect Hsp70 favors the ADP-bound state in this complex. 
Because the ADP-bound form of Hsp70 has a tighter affinity for clients, this 
conformation might provide a way for stimulated PP5 to be held in proximity with Hsp70-
bound clients for a length of time that is sufficient to allow dephosphorylation. In turn, 
this mechanism would limit the phosphatase activity of PP5 once it leaves the 
chaperone complexes, providing a reversible switch that responds to chaperone activity. 
Surprisingly, we found that in the context of the full-length protein, Hsp90 interaction 
appears asymmetric and likely weaker compared to Hsp70. This is in contrast to the 10-
fold tighter affinity we identified for the Hsp90 MEEVD motif compared to the Hsp70 
IEEVD. Thus, Hsp90 might use a different mechanism potentially involving client 
interactions or Hsp90 conformational changes that enable accessibility to the MEEVD to 
enhance PP5 interactions with phosphorylated clients. 
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Finally, these results point to the Hsp70-PP5 and Hsp90-PP5 protein-protein 
interactions as potential drug targets. PP5 has been proposed as an anti-tumor target 
[9], but the active sites of PPP family phosphatases are highly conserved and it has 
proven difficult to identify selective inhibitors. Based on our results, inhibitors of the PPIs 
between PP5 and the molecular chaperones might be an attractive alternative. 
Specifically, inhibitors of these PPIs might be expected to dysregulate kinase-
phosphatase balance through multiple mechanisms, disconnecting PP5 from a major 
activation pathway and disrupting its chaperone-mediated ability to locate clients.  
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Appendix Figure 2-1.  SRL-PFAC confirm that both Hsp70-PP5 and Hsp90-PP5 
interact. (A) Schematic diagram of plasmid constructs. The two interacting proteins 
Hsp70/90 and PP5 are fused to NRL (amino acids 1–229) and CRL (amino acids 230–
311) portion of the RL, respectively through a (G4S)2 peptide linker. (B) Schematic 
diagram of the SRL-PFAC system for monitoring complex formation between Hsp70/90 
and PP5. Interactions between Hsp70/90 and PP5 bring CRL and NRL in close 
proximity, ultimately resulting in the complementation of RL enzyme activity and photon 
production in the presence of the substrate coelenterazine. (C) SRL-PFAC system is 
sensitive for monitoring complex formation of Hsp70/90 and PP5 and shows highly 
complemented RL activity and low background. HEK293 cells were transduced with 
either Hsp70-CRL, Hsp90-CRL, NRL-PP5, Hsp70-CRL + NRL-PP5, or Hsp90-CRL + 
NRL-PP5.  Data are presented as mean ± S.D. (n = 3). ***  p<0.001 compared to 
control 
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Appendix Figure 2-2.  Fluorescence polarization confirms that Hsp90-PP5 has 
higher affinity than Hsp70-PP5. (A) Raw mP values were plotted with control peptide.  
No binding was observed with increasing concentrations of PP5 and control peptide at 
20nM. (B) Direct binding was measured with increasing concentration of PP5 and 5mer 
peptides (20nM) (C) Direct binding was measured using increasing concentrations of 
purified full length PP5 with 5FAM 10mer labeled peptide (20 nM). (D)To see how the 
residues M and I contribute affinity to PP5, HSP70-90 peptides were synthesis so that 
HSP90 10mer peptide contained an I instead of an M and HSP70 10mer peptide 
contained an M instead of an I.  FP was performed with increasing concentrations of 
PP5 and both peptides were held constant at 20 nM.  Data are presented as mean ± 
S.D. (n = 3). 
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Appendix Figure 2-3.  Competition studies confirm binding data.  (A) Competition of 
5FAM-HSP90α (20nM) with increasing concentrations of unlabeled tracer (HSP90α, 
HSP90β, HSC70, HSP72 peptides). (B) Competition of 5FAM-HSP90β (20nM) with 
increasing concentrations of unlabeled tracer (HSP90α, HSP90β, HSC70, HSP72 
peptides). (C) Competition of 5FAM-HSC70 (20nM) with increasing concentrations of 
unlabeled tracer (HSP90α, HSP90β, HSC70, HSP72 peptides).  (D) Competition of 
5FAM-HSP72 (20nM) with increasing concentrations of unlabeled tracer (HSP90α, 
HSP90β, HSC70, HSP72 peptides). Data are presented as mean ± S.D. (n = 3). 
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Appendix Figure 2-4.  Hsp70-PP5 and Hsp90 interact with different stoichemetries.  
PP5 binds intact Hsp70 and Hsp90. (A) SEC-MALS analysis of Hsp70:PP5 (blue) 
shows elution volume shift and molecular weight of 145 kDa, indicating stable 1:1 
complex compared to Hsp70 (red) and PP5 (green) alone. (B) Hsp90:PP5 (blue) is 
shifted in elution volume and determined to be a 2:1 complex at 232 kDa compared 
Hsp90 dimer alone (red).  Molecular weights determined from the Raleigh ratio, 
measured by static light scattering, and the protein concentration (right Y-axis), 
measured by a refractive index detector are indicated. Molecular weights based on 
sequence are: 70 (Hsp70), 56 (PP5) and 170 (Hsp90 dimer). SEC columns WTC-030S5 
and WTC-050S5 (Wyatt Technology) were used to optimally separate free Hsp70 and 
Hsp90 from PP5 complexes, respectively. 
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Appendix Figure 2-5.  C-terminal residues of Hsc70 bind PP5. (a) Full 800 MHz 
TROSY spectra of 15N-labeled Hsc70 alone (blue) and in a 1:1 mixture with PP5 (red). 
(b) High-contour view of spectra with resonance assignments. (c)Schematic diagram of 
the disordered C-terminal tail of Hsc70. Unassigned residues are shown in gray. 
Residues from Hsc70 that are unaffected by binding the binding of PP5 are depicted in 
black; those that disappear or shift are shown in brown and green, respectively. 
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Appendix Figure 2-6.  Hsp70 preferentially stimulates PP5’s phosphatase activity.  
p-nitrophenylphosphate substrate was added at a concentration of 4.5mM to each well. 
(A) Represents enzymatic activity. ( B) Represent the raw OD values; this confirms that 
the phosphatase is not due to ATPase from Hsp70 or Hsp90 alone. Data are presented 
as mean ± S.D. (n = 3).  *** p<0.001 compared to Hsp90-PP5.  +++ p<0.001 compare 
to Hop-PP5.   
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Appendix Table 2-1.  Peptides used in fluorescence polarization assay. Hsp70/90 
C-terminal peptides used in fluorescence polarization assays. For binding experiments, 
each peptide tracer/probe contained an amino-terminal 5-carboxyfluorescein (5FAM) 
labeled. Labels were connected to peptides through an aminohexanoic acid (AHX) 
linker. Additionally, for competitive binding experiments, each unlabeled peptide 
competitor contained a free amino-terminal end. Mutant residues in the C-terminal 
tracer are highlighted in gray. 
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Appendix Table 2-2. Summary of NMR. (a) The rotational correlation time c was 
estimated from the molecular weight following reference [43]. (b) The average amide 
proton and nitrogen linewidths (LW) at 800 MHz were calculated from coordinates of the 
crystal structure of ubiquitin as a model, using different rotational correlation times. The 
calculations took into account all dipole-dipole interactions with all magnetic nuclei in the 
molecule, and 1H CSA or 15N CSA relaxation.  1H-15N dipolar / 1H CSA or 1H-15N dipolar 
/ 15N CSA cross correlated R2 relaxation was taken into account for the columns marked 
“TROSY”.  We assumed uniform 15N labeling, no 13C or 2H labeling. (c) In TROSY there 
are three transfer periods with 1HN coherence, that all are tuned to 1/2JNH (5 ms). The 
transfer efficiency is reduced by 1H R2 relaxation. In total, I=I0 (exp(-3.1416*LW*0.005))
3 
.   The relevant linewidths during these transfers are listed in the column marked “1HN 
HSQC LW”. (d) The peak height for 10 kDa was taken as a standard. The peak heights 
for other molecular weights were computed by taking the ratio of the relevant transfer 
efficiencies divided by the ratio of the relevant 1H TROSY linewidths (the latter affects 
peak height during data acquisition). The effect of increasing 15N linewidth on the 
TROSY peak intensity is minimal because of the short 15N  acquisition time used, and 
was not included in the calculation. 
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  Appendix 3
High Throughput Screening for Small Molecules to Block TPR containing Co-
chaperones- Hsp90 Chaperone Complex 
Abstract 
 Heat Shock Protein 90 (Hsp90) is involved in a complex which facilitates the 
maturation of many oncogenic client proteins.  For this reason, targeting this complex 
for cancer therapy has been an interest for many.  In this study we performed a high 
throughput screen (HTS) to identify small molecules to inhibit this complex.  A subset of 
co-chaperone proteins, known as tetratricopeptide domain (TRP) proteins, are known to 
bind to Hsp90 to aid in client folding and help HSP90 carry out its function.  Therefore, 
we believed that if we inhibit these Hsp90-TPR domain containing proteins, it would 
provide a novel approach at targeting cancer.  In this study, we screened two different 
protein-protein interactions; Hsp90-PP5 and Hsp90- HOP.  We optimized our screen 
using a fluorescence polarization platform and looked at over 140,000 small molecules 
with these two interactions at the University of Michigan Center for Chemical Genomics 
(CCG).  Our findings suggested that the TPR containing proteins -Hsp90 interactions 
are difficult to target and to find a specific yet druggable molecule for therapeutic 
purposes.  Perhaps a peptidomimetics would be a better option for targeting this 
interaction.    
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Introduction 
Hsp90 interacts with co-chaperones to form a complex which regulates the 
maturation and activity of many oncogenic proteins in disease states.  To date, various 
Hsp90 inhibitors that bind to Hsp90 at its ATP-binding pocket have reached preclinical 
and clinical trials [1-4].  However, many limitation of these compounds for clinical use 
have failed due to toxicity [5].  Therefore, alternative strategies in inhibiting Hsp90 
function should be explored. One innovative approach is targeting protein-protein 
interactions (PPI) between TPR contain proteins that bind with Hsp90 [6, 7].  The C-
terminal residues, MEEVD of Hsp90 has been recognized to bind to co-chaperones that 
contain TPR domains [8-10].  Therefore, we hypothesized inhibiting the MEEVD-TPR 
interactions would alter Hsp90 function and degrade a subset of oncogenic proteins, 
which would provide more specificity and selectivity against cancer cells. 
TPR containing proteins are highly conserved having tandem repeats of 34 
amino acids.  Both Hsp70 and Hsp90 are found to be “universal acceptors” for TPR 
proteins [11]. Co-chaperones that interact  with Hsp90 that contain TPR domains are 
Protein Phosphatase 5 (PP5),  Hsp70-Hsp90 Organizing Protein (HOP), Carboxy 
terminus of Hsp70-interacting protein (CHIP), and FK506 binding protein 51 kDa and 
52kDa (FKBP51 and FKBP52) [11-16].  The presences and mechanisms of many of 
these protein interactions remain unclear.  However, there has been an association 
between these TPR containing protein malfunction and disease states [12].   
Both PP5 and HOP are two TPR containing co-chaperone proteins that interact 
with the complex.  The function to date of PP5 is unknown and controversial.  However, 
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it has been shown in many studies that it is involved in cell signal transduction [17-19].  
Furthermore, PP5 possesses auto-inhibitory domain and maintains low basal activity.  
In order to relieve this autoinhibition, studies have concluded that Hsp70, Hsp90, or 
arachondonic acid needs to bind to PP5 [20-24]. HOP’s function is still not fully 
understood to date, but it has been shown that HOP facilitates Hsp70 and Hsp90 
binding as well as shuffle client proteins between the two chaperones [25].  Similarly to 
Hsp90 in the disease states, both HOP and PP5 expression have been positively 
correlated in cancer.  PP5 has been shown to be overexpressed in human breast 
cancer tissue as well as its expression aiding in breast cancer cell growth (in a MCF-7, 
an ER+ breast cancer cell line) [26, 27].  In addition, the role of HOP has also been 
implemented to be important in a disease state.  In one study, it was shown that knock 
down of HOP using siRNA in colon cancer cell lines decreased cell viability [28].  These 
studies provided evidence for the importance to inhibit Hsp90-TPR domain containing 
interactions.   
Although the affinity of these interactions vary, many of these TPR proteins bind 
to Hsp90 similarly through the positive residues of lysine and arginine, known as the 
carboxylate clamp [20]. Therefore, we proposed that inhibitors to TPR co-chaperone-
Hsp90 interaction will ultimately be an effective way at targeting the Hsp90 complex.  
Our hypothesis is that small molecules to block the TPR-Hsp90 interaction will 
ultimately decrease cancer cell viability by degrading oncogenic client proteins that rely 
on maturation from this PPI.  
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Material/ Methods 
Reagents  
The peptide expressing Hsp90 10 C-terminal peptide (5FAM-DDTSRMEEVD) 
was purchased from Biomatik (SPR001).  Black 96 well plates and 384 well plates were 
purchased from Corning (3792 and 3676).  Follow up compounds were purchased from 
ChemDiv (cat #: D077-0329, 2039-0579, G756-0219, N025-0039, G756-0234, G617-
0103, 4984-0429, 3389-1518, and 8407-0790).  The following compounds were also 
ordered; Trans-2-phenylcyclopropylamine HCl (Sigma p8511), dihydrotanshinone I 
(Sigma D0947), and suramin (Calbiochem 574625).      
Fluorescence Polarization Assay:   
All fluorescence polarization (FP) experiments were conducted in 384-well black, 
low volume, round-bottom plates (Corning 3676) using a BioTeck Synergy 2 plate 
reader (Winooski, VT).  For binding experiments, to each well, we added increasing 
concentration of full length protein and the 5-carboxyfluorescein (5-FAM) labeled Hsp90 
C-terminal probe/tracer.  For screening compounds each well had PP5 protein at 100 
nM or HOP protein at 4 µM concentration (equivalent to the Kd), 5-FAM Hsp90 10-mer 
peptide was held constant at 6 nM for PP5 or 3 nM for HOP, and compounds or DMSO 
were pin tooled into each well.  All wells had a final volume of 20 µL in the assay buffer 
(for PP5 the assay buffer was 40 mM Tris-HCl, pH=7.4, 10% glycerol, 1mM DTT, 0.1% 
tween 20 and for HOP the assay buffer was 20 mM Tris-HCl pH= 8.0, 50 mM NaCL, 
1mM DTT, 10% glycerol, and 0.1% tween 20). The plate was allowed to incubate at 
room temperature for 30 minutes to reach equilibrium.  The polarization values, 
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millipolarization units (mP) was measured at an excitation wavelength at 485 nm and an 
emission wavelength at 528 nm.   
High Throughput Screening:  
All screening was performed at the Center of Chemical Genomics (CCG) at the 
University of Michigan.  For PP5; the screening libraries included the biofocus NCC, 
focused collection, and MS spectrum which totaled to 4160 compounds.  For HOP, 
100,000 compounds were screened in the ChemDiv library.   
The FP assays were optimized in the CCG laboratory with detergent and DMSO.  
For primary screen (n=1), each compound was pin tooled using at Biomek FX liquid 
handling robot into the wells at 10 µM (0.2 µL).  For the positive control on each plate, 
5-FAM was used alone for the negative control 5-FAM, protein and DMSO was used.   
The positive and negative controls were used to calculate the Z’ factor for the assay 
(see equation below); each plate assays was considered acceptable if the Z’> 0.5.  
Compounds that showed activity and were at least 3 standard deviations (3SD) above 
the negative control were next analyzed in a dose response curves (DRC). 
𝑍′ = 1 −
3(𝑋𝑝 + 𝑋𝑛)
𝑆𝐷𝑝 − 𝑆𝐷𝑛
 
 
Where Xp is the average of the positive control, Xn is the average of the negative 
control, SDp is the standard error of the positive control, and SDn is the average of the 
negative control.   
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DRC compounds were added to wells ranging from concentrations of 100 µM to 
1 nM, compounds were ran in triplicate for DRC to eliminate any false positives. Each 
compound was added to each well using a TTP Labtech Mosquito X1.  Each well was 
verified that signal detection was not a result of quench signal or that the compound 
was fluorescent.  Leads from the DRC were repurchased for confirmation and 
secondary assays.     
Results 
Optimization of the Fluorescence Polarization Assay 
A fluorescence polarization (FP) assay which relies on the rotation of the protein/ 
protein complex was established for full length HOP and full length PP5 proteins with a 
10-mer peptide (DDTSRMEEVD) corresponding to the C-terminal of Hsp90.  The FP 
assay depends on the labeled peptide to measure the fluorescence; when the labeled 
peptide is free (no binding); rotation of the peptide in solution occurs at a higher rate 
which produces a low mP measurement.  Whereas, when the labeled peptide is able to 
bind to the protein, the larger complex slows down in rotation corresponding to a high 
mP reading.  To demonstrate that the Hsp90 was indeed able to bind both HOP and 
PP5, a dose response curve was established for this interaction using increasing 
concentrations of HOP or PP5.  Figure 1A verified that the binding affinity for PP5-
Hsp90 10-mer was on the low nanomolar scale (66 nM), which provided an ideal 
binding affinity for screening small molecules.  This result was confirmed using a 
competition assay; the unlabeled peptide of Hsp90 10-mer (DDTSRMEEVD) was able 
to compete away 5-FAM labeled Hsp90 10-mer peptide at an IC50 of 19 µM (Figure 1B).  
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In addition, we established the FP assay with HOP-Hsp90.  Figure 1C showed 
the binding affinity for HOP-Hsp90 peptide was 4.8 µM.  Similarly, we validated this 
platform by performing competition studies with HOP-Hsp90; however, because HOP 
has 3 TPR domains that essentially can bind the Hsp90 peptide, this was a little more 
difficult to confirm (Figure1D).  Whether this curve represents a composite binding 
affinity or just the affinity to TPR2A is unknown.  We continued screening because we 
thought that having multiple TPR domains would be beneficial for discovering an 
inhibitor to this interaction.  Although this affinity was slightly higher than PP5-Hsp90 
interaction, the affinity was still in an acceptable range for screening purposes.  We 
optimized both platforms with DMSO and detergents.  
Primary Screens for HOP-Hsp90 & PP5-Hsp90 
After optimization, a high throughput screen (HTS) was performed.  To begin with 
we started screening using a primary assay for small molecules from the biofocus NCC, 
focused collection, and MS spectrum library at the CCG.  In the primary screen, each 
small molecule was tested once at a single concentration using various libraries.   
Figure 2A shows all the compounds screened for the PP5-Hsp90 interaction in 
terms of the percent inhibition for each small molecule and figure 2B shows all the 
small molecules screened for HOP-Hsp90.  The positive control consisted of wells that 
only contained 5FAM only (indicated by red dots).  The negative control contained 
5FAM, PP5 protein, and DMSO (indicated by the blue dots).  Finally each of the small 
molecules that were screened is indicated by the green dots. Compounds were 
considered to be a lead for further pursuit if they were 3 standard deviations (3SD) away 
 
 
170 
 
from the negative control (indicated by the solid red line).  Table 1 summarizes this data 
by libraries screened including; hit rates, total hit compounds for each protein 
interaction, as well as the breakdown of each inhibition for each compound.  For the 
PP5-Hsp90 interaction, we screened about 3391 compounds and had a hit ratio 
between 3.65-6.14% which was about 165 hits total for this interaction.  For the HOP-
Hsp90 interaction, we screened a lot more compounds, about 100,000 however, how 
the hit ratio was way less ~0.27% equaling about 269 hits.   
Dose Response Curves Testing 
A total of 434 compounds that were considered a hit and were also above 3SD 
from the negative control were carried on to dose response curves (DRC).  Here, 
compounds were run in triplicate at concentrations ranging from 0.1 nM – 100µM.  
Figure 3 shows 14 compounds that produced a dose response curve.  During the DRC 
testing, we also verified that none of these compounds were fluorescing or quenching.  
In order to do this, 5-FAM was added to the plate first and the fluorescent values were 
read.  Directly following, compounds were added to see if the fluorescent values were 
quenched compared to the original reading of the 5-FAM label alone.  Finally, protein 
was added for the final analysis.  Figure 4 shows the 14 compounds structures that had 
pAC50 of >5, meaning the log of the activity (in this case inhibition or IC50) were on the 
sub-micromolar.  These fourteen lead compounds did not show any quenching or 
fluorescent effects instead retained activity of pAC50> 5 (Table 2).       
The top leading compounds from the DRC that still showed inhibition and fairly 
good activity (pAC50 of 4 or 6) were then purchased, made fresh, and retested in the 
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FP platform.  We ordered 14 of these compounds to prepare fresh in DMSO solution at 
10 mM and retested in the FP platform.  The final percentage of DMSO was less than 
0.02% for each well.  The only compound that retained activity after being test after 
being freshly prepared was suramin.  The rest of the compounds showed no activity in 
either the PP5-Hsp90 or HOP-Hsp90 platform.   
Suramin inhibition of Hsp90-TPR containing proteins   
Suramin was the only compound that remained a lead when retested fresh in FP 
platform for Hsp90-PP5.  This compound showed an IC50 value of 6.2 ±0.6 µM. (Figure 
5).  Since many TPR containing proteins- Hsp90 have similar binding, via the positive 
lysine and arginine residues in the carboxylate clamp, we were curious to look at the 
specificity of this interaction compared to other Hsp90-TPR containing proteins.  
Therefore, we used full length HOP and Hsp90 10-mer peptide as well as full length 
CHIP and Hsp90 10-mer peptide to see if suramin also was able to block this 
interaction.  As suspected, it was able to block the interaction at an IC50 of 8.7 ± 0.37 µM 
and 7.43 ± 0.47 µM respectively.   
Optimizing Suramin 
Although, suramin showed inhibition against TPR-Hsp90 interactions, suramin 
was far from a drug like molecule.  Two apparent issues from just the structure alone 
were that it was highly charged and has a large molecular weight which would make it 
difficult for this compound to cross cell membranes (Figure 6A).  We therefore decided 
that we would try to modify the compound and see if we could retain activity.  Figure 6B 
shows several analogs that were synthesize.  Since suramin is a dimer we tried to 
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synthesize the monomer version (figure 6B i and ii) and we also tried to keep the dimer 
but reduce the charge (figure 6B iii).  However, when these changes were made, 
activity for blocking Hsp90-PP5 activity was lost (as well as activity for HOP-Hsp90 and 
CHIP-Hsp90).   
Discussion 
 Targeting Hsp90 chaperone complex has been a challenge for many years.  
Initially targeting the ATPase of Hsp90 with geldanamycin and derivatives seemed 
ideal; however, after entering clinical trials it was soon realized that these compounds 
tend to have low affinity, high toxicity, and solubility issues.  Alternative approaches to 
target Hsp90 are to target PPI.  This too presents many problems.  In this study we 
have presented work that targets a group of proteins that interact with Hsp90 called 
tetratricopeptides domain containing proteins, specifically Hsp90-PP5 and Hsp90-HOP.   
We found that these interactions are difficult to find a specific inhibitor that selectively 
binds to the TPR domains.   
In this study we screened over 140,000 compounds in which none were able to 
specifically inhibit TPR containing proteins-Hsp90 interaction.  In addition, Lynn 
Reagan’s group had already performed a HTS screen with Hsp90 and  the 
tetratricopeptides containing proteins, HOP [30].  Although this was performed, we still 
felt that we could find a new chemical entity.  The previous screen with HOP consisted 
of an alpha screen of the TPR2A domain of HOP and the C-terminal of Hsp90.  The 
binding affinity for this interaction was slightly higher than the FP binding affinity used in 
this study (11 µM vs of 4 µM).  In addition, we were screening with full length HOP 
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instead of one domain (TPR2A), this opened up the possibility for finding compounds 
that could block either TPR1 and/or TPR2A domains of HOP or a compound specific to 
TPR2A.  Finally, the screen performed previously with HOP by Regean’s group was 
done at the National Cancer Institute- NIH Chemical Genomic Center (NCI NCGC).  
Comparing the NCI NCGC chemical library with the Center of Chemical Genomics 
(CCG) at the University of Michigan, there was only a 5% overlap in compounds.  
Regean’s group screened nearly 97,000 compounds.  Together, these screens suggest 
that the Hsp90-TPR containing proteins are not ideal for targeting Hsp90.       
Unfortunately, the results that are suggested from our data were unsuccessful at 
targeting these PPI.  These results suggest two things; one being that the small 
molecules in the Center for Chemical Genomics (CCG) may not be suitable for these 
PPI.  We screened close to 140,000 compounds, in which only one compound, suramin 
was able to show any type of activity in vitro when fresh compound was prepared. Our 
lab did performed extensive follow ups with this compound.  As mentioned and seen, 
this compound is highly charged and has a large molecular weight.  Although this is 
obviously, we still try to treat several breast cancer cell lines with this compound using 
an MTS assay in hopes to see efficacy by decreasing in cell viability.  However, when 
treating cells with this compound up to 100 µM, no difference in cell viability was seen 
compared to control (data not shown).  In addition to suramin being highly charged and 
having a large molecular weight, this compound has been found to be highly 
promiscuous meaning that this compound hits in many other PPI screens. Due to the 
fact that Suramin violated many of Lipinski’s rules, this was not surprising to us.  This 
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led us to believe that suramin could possibly be a protein aggregated due to it being 
highly charge and having a big bulky molecular structure.  
The second suggest for obtaining unsuccessful results in this screen is the 
nature of the binding pockets on these TPR containing proteins.  Despite having 
relatively good affinity for Hsp90, both HSP90 and PP5 have hard pockets to target. 
After performing some modeling simulation it was clear that these pockets are shallow 
and surfaced expose making it difficult for molecules to bind in these binding pockets.  
Although those results were not what we hoped for, there are many other co-
chaperones that associate with Hsp90 that may be ideal for targeting PPI within this 
complex such as Hsp90-p23 or Hsp90-Cdc37.  Or an alternative to a small molecule 
would be a peptidomics of the residues MEEVD for delivery purposes.    
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Appendix Figure 3-1.  Fluorescence Polarization Assay. (A) FP was performed with  
increasing amounts of full length PP5.  5FAM-Hsp90 10mer peptide was held constant 
at 6 nM.  (B) Full length PP5 (at 100 nM) and 5FAM-Hsp90 peptide (6 nM) interaction 
was competed away with increasing concentrations of unlabeled peptide. (C) FP was 
performed with  increasing amounts of full length HOP.  5FAM-Hsp90 10mer peptide 
was held constant at 3 nM.  (D) Full length HOP (4 µM) and 5FAM-Hsp90 peptide (3 
nM) interaction was competed away with increasing concentrations of unlabeled 
peptide.  Data represents as a mean ± standard deviation (n=3). 
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Appendix Figure 3-2.  Primary Screen of TPR containing proteins-Hsp90 peptide.  
(A) Primary Assay for Hsp90-PP5.  (B) Primary Assay for Hsp90-HOP.  The negative 
control is indicated as the blue dots, the positive control is indicated as the red dots, the 
solid red line indicates 3SD way from negative control, and the green dots indicate the 
small molecules screened.   
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Appendix Figure 3-3.  Dose Response Curves from Hit Compounds.  The data 
reflects the average dose response curves with inhibitors against (A) Hsp90-PP5 
interaction or  (B)  Hsp90-HOP interaction 
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Appendix Figure 3-4. Hits from DRC. Compounds that were still leads after DRC and 
maintained activity of pAC50>4 (n=3). 
 
 
 
181 
 
 
Appendix Figure 3-5. Suramin inhibits TPR containing proteins-Hsp90.  Increasing 
concentrations of suramin was used to measure the percent inhibition between TPR 
contain proteins and Hsp90. 
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Appendix Figure 3-6.  Sumarin and Analogs for inhibiting Hsp90-TPR containing 
proteins. (A) Suramin was made in a fresh stock solution and the FP assay was 
repeated.  Suramin was able to block the Hsp90-PP5 interaction at an IC50 of 9.06 µM.  
(B) Analogs of suramin to eliminate charge and mass were produced.   
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Appendix Table 3-1.  Summary of Primary Screen for TPR-Hsp90.  (A) Indicated that 
hits, percent inhibition for each hit, and library for each small molecule for the Hsp90-
PP5 interaction.  (B) Indicated that hits, percent inhibition for each hit, and library for 
each small molecule for the Hsp90-HOP interaction.  
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Appendix Table 3-2.  Summary of Dose Response Screen for TPR domain- Hsp90 
peptide.  MS Spectrum2000, BioFocusNCC, Focused_Collection, and 
MS2000_NCC_Focused were screened against the Hsp90-PP5 interaction.  The 
ChemDiv 1000 was screened against the Hsp90-HOP interaction.   
 
